var title_f6_17_6416="First degree AV block III";
var content_f6_17_6416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    First degree AV block with a prolonged PR interval and wide QRS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 128px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACAAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6QEWEiB0lB+86bk4561WgiBudWH9mx9V43Lz8gp/2+wKRH7Zcf63HVvXv7Vx958RvD2m63rdmza1cywsiyNa2csyodg43Adad0eklNJ3X5915nerGPtIzp6D5OuV45pjx4iiH2FB++HGV9TzXEJ8UtBa6UrZ+KCdmMf2XPj69KZL8U9Bjt4mks/EyosuS7aZNgcnqcdKfMjFKWmn5/wCZ2lvGDd6mTYJnK915+QVKkQM9l/oSAeW393jhazNI1rTr/wC23drPcS206RyxuFbBRkBBH51dTUbZbiyA+0n922P3bc8L1pJqxrOFS/wvbz/l9SwYh9lOLCPPmHjK/wB6q0MWNX1TbZxnMUeOR83DflTDqNt9hODeEeaeQjZ+9UUV9bHWNUO285hj3Yjbj73SnccadS0tPz7rzNSNG3Wp+xoCEOTkfJ06U7Y32c/6LGD5vC5Hr1qpFewFrPCX+dvy/u2weB1prX1stu2YdR2+byfKfOc07mXs5t7fn3fmPCt/auq/uk/49osHPX/WVbBnJtcRRY28nPTjtWPJfxDUtVJt74hraMHEL8f6ypkvoA1oRbapwvH7qTB471KZc6U306L/ANJXmaWJwj+XFDnzemfcc/WqW2Y6nqx2w4MEY6nJ4brUAvrcxyA2eq48/P8AqnznI/SoDewDUNTJtNSJaFAcRP6NQ2ioUpLm0/q68zbY3IngAWDG055PH0qqn2z7PJlIAftQ7npvFVftdv59u32HVsqpA/cyfrUJu4BA/wDoWqHNyG/1T/3xRcUaMtNPw8/UvW/2oatqRVYCdkeOTycGrcTXRe3ykGDHk4J4+lYltdwf2tqJ+xaocon/ACyfnirMN3AHtsWOqZ2EDMb8fXmmmh1KUu3Rfl6mhIboQL8sOTOO56b6itzc/wBq6gNsO3amDk9cVTN3H5GPsGpDE+cbG5+br1plteJ/auoYsb/JRB9w8jHTrSuJUpcstP6uvM0o/P36eSIvuHdgn+6OlEhufsdxgQZ8w4yTjGaopcbX07FjffKjDoePlHvTHuCbGcHTb0/vCcc+vXrTF7J3Wn5d35l2Mz/29ehfK/494yuSfVutWovtOLUsYc7fnxn07Viib/if3rHTrok2yA/7XzN71KkvFljSLo7fu5I+XjvQmOdJu3ou3b1NUm68iT/UB9/HXGM96rjz/wC3LsAxbfssfXOc7pKpSyt9nnH9jTkGTONw+bpzUSyuddu2GkSbjaoPvL/eehijRdpbbeXdeZtr5+LTmP8A2sf7p6VG/nCO62tED5owSO3y1RSaULagaM4APHzLxxTJWmMV3/xJ9374HBdOfu0Eqk79PvXf1L487+2yN8e37P0wc/ep8P2nyrb54fvHdweRz0rKJl/tznRlybfrvTpuog80W9qP7CXG88GROOtK5UqWi1Wy/l7PzNhxdFZwJYQf4cqeB71Uxc/28oLxH/Rj2P8AeFVpRLsuf+JBGfX95H83FVdkn9vRn+woubY5+eP+8KLhTpb6rZ/y9vU2lW7KW/76DIY5O088Gm3H2oW95++g4U4+U/LxWdGkght/+Kei4b7pkj4680XEchguydAhGVPPmR88fShsFT97df8Akvf1LYFx/b6bpIifsh6Kf74qZBcm2j3Sw58wZ+U8/N0rI2zDX48aJCP9FIx5if3x7VKqTrbRj+w4BiUdJE/vfShMqVL4dV0/l8/M1ZPtO26xNCMDj5fu8d6rjz/+EhAMkX/HpyMdfmqA/aM3X/EjgI4wDInzcd+Kr/6QddU/2PD/AMevI8xePm6dKGyYU9Hqtu8ey8zWHnC2tsyxZ8wZOOvPSg+b/p/72NTuGDj7vyLWaRd/Z7f/AIksAIkBwJV4GevSnlrplvf+JRCTkYBlXn5R7UXF7LzX3x7rzLLlhr8AMqAm2PGOvPWpw7iKHN3ECZDk7R83J4FZRa7/ALagY6ZEGFuw/wBaPWravf7Ih/ZkAw/TzR8oyeRxRcJ09I6rbvHzJ5ywiu/9LQHcOcD5eBUMjH+3bUfa1P8Ao75XA55XmmSyX4W6xp8JBYY/ejngVE8mof23bN9ghB8hwT5o45WhsIQfls+q7EsUmbW2xfID55ycLzy3FSyyjfer9vQEIMcL8vB/Oq8Uuo/ZrfFlAD5x483py1Plk1HN4fslucxjH7zrwetA3D3nt967kbSp/bNl/wATBB/oz8YXnleamWdfLz/ayf63721PyqqJdS/tiyP2O3H+jPz5vulWEk1QRf8AHnbZ83OPMoRUo6LbbvHu/IfLOpF0v9qJwnonHBqFpR/a9p/xMlOYH5wnPK1LLJqn+k4tLflOP3vXg9agebVBq9n/AKLbZMD7v3nTlen6UNihH02fWPb0JpZQbYH+1FP71edqf3xxThKomuc6ooAC9k44pksuqfZhutbYHzl48ztvFP8AM1PzrrbbW2dq4y554707k8uj2++Pl5FWaRWv9LI1QHO/Hypz8hq156C3c/2qow5+banHPSqc0mqfbdJ3QWo+/wDxnrsNWy+r+Q+ILLO89XOCM0ky5x0jt967vyLQNyY0Pm25Pm4J2nkZ6DnrXCfDCSaW98dMkke8a1OuSD1HHr04rtljQQx4sgB53Tjj5utcN8JFRl8ZutvuVtbu+OOf3h4oe6JglyT/AOB/Mj0ZfO80ZeIjbyADn+dUNVjlm0qSPzIgWLAnHGOeKuICJUxbBRs+9kce1VbhWNmFFmv+tP7vcPU80znitf8Ahjk/hLJNJ4Ktg0yfu7aKIccrsjC8/lXZRlvOsv3i4MTZGPvcL0rhfg8ZH8KT+ZaJuWWSPORztdhjp2xXboCJrH/R0DCJsfN93heOlTHY3rr336eX8ouXFmxM6j96eccfe6VDEH/tnUj5wC+THgYHy/f604iQ2LgWaf6wnbvH97r0qOPzDrOog2yHMEX8Y+bl/amRFaS/4HdFyPdi2zcDkeg+bjtTZC3kn/ShnzQN2B6jikjEmLfNnGNowDvHy8fSlKyFSPsUeN+cbxz056UzO2v/AAxSfd/ampAXO3FtHxgZ/wCWlWV3f6N/pvVfReePpVRxJ/auo4s42P2ePkuOfv8AtVnbJutc2EXTk7x8vH0pI2mtvRdv5RW3COQrfY/ejkqvHI46VUAb+09Txe4/cpxtX0b2qyFk2Sj7BCf3vTeOeRz0qsiyf2pqAFlEcxJzvHo3tTY4bS228u6LoDLLADfZ+U/wrz+lQNu8h8XuP9KA+6v98cdKsBHaSEtYxDCn+MHb+lQMJBA2LOI/6SP4h03jnpQRHdf8DuMtwRrWof6ZgiOPjavHHWrVuCfsubrd8h42r83H0qrbq51q/wA20P8Aq0xyOePpVqEOq2gEEX3OTnpx24oQ6v6Lt2GuCIObv/l4HOB/e6VDB/yGdS/0ggiNMrgfLx1q2Vk8rAiiH74Hr23dfrUEG/8AtfUQEjC7Ew3fOO/tQyYvSXp5d0LGw8zTh9ozmM8cfN8oqOR0+w3Obs/60jIxxz06VKiy79OI8sYQ5/75HSmyC4+xXO3yM+Y2Bg469+aBq11/XV+RXjli/wCEjvgbrkWseRx8vzNVhJIgLL/TTnt0+fj6UyMT/wDCQ3RBhx9ljxwc/efrzVlBdeXb4e37bvlPp25pIdRq69F+XoQSywGCcPfsAH5ORlenHSq3nQHXbnF4cm0TjI/vPzV6Q3nlzfPbZDgD5TjHHXmq3+mf25Pte2x9lTqp/vP702OFrP0/y8h6TW+20/05j+I54+lQTT23lXe6/Zf3w5DDj7vtV4fbdsH7y1yTz8renbmopPtnlXJ8y2P7wY+U8fd96BRav/Xf0Kgnthr2f7Qb/j36bh/e+lOintRBaZ1J/vnB3D5vve1Tf6Z/boBkttv2c/wnP3h70+3+1mC1PmW2d5z8px0bpzSLk42Xov18iEzWzC7xqLnjn5h8vH0qHzrf/hIIz9vY/wCikYyP7y+1aDfasXRMlvwOPlPHHfmoR9o/t6LMkO37MeApz95femTGS19H+XoNhlt/KgJ1CRsOcHPXr7Us8tuYb7/TZD8p3AH7vHarGbry4f31vnfhjtOCPQc9aW4+0GC7AlgHynYdp+XjvzTI5lf+u/oUleI+IYsXLHNmcc9fnHNSKYvs0GLqVv3wxz1+boaAJ/8AhIY8yREfZDkBT13j3qUed9khzNET5y5IHBG7p1qUXJr3fl+vkDvEwvSZpgOA2M8fL2qD5P8AhIov3k2TZ8cnBG7qfermJi13tmjB425X7vy9+arDzP7djzKn/Hqc8dfm602TB7+n6LyHN5Qtrb57gjzRjJOSc96HEYW/z9oxuGcFs/cHSpcyG3gzcRs3mDLAcHnpTW80C+/0hOo25A4+UdaBJ+f9XXkVWEY163wLosbdupbGM/XrVhREIohtvMeYcctnOT156VFJ5n9t2hNwhBgfjA68c1aXzTHHi7jyHOTtHzDJ4pFTekdenn5+RDN5RjuRsvOvOC/oOnNV38v+27X5L3PkP3fHVevNXpBJtnxdoMkYyB8vAqtJ5n9t23+lJ/qH4wOeVoYU359H37ehXTyfs8H7rUMCY9C+ere9LKYd17+61H/VjvJ6HpzUq+b9nt/9MQHzjztHPLU+YS7r4i8THljA2jjg0y+bV6/i+/oUMQ/2pYnytR/493H3pP8AZ96sDyPJP7jVMCX+9Jnr9elAMv8Aa2nj7WmPszkjaOfuVZIm8lj9tQHzuu0YPI4oQ5y+HX8X3fkQMIC10TDqQynJLSYPB6c1A4hGr2QEWof6h8fM/qvXmtF/NzdqbtDiPgbR8vBqu5f+2NPAuVOYXzwPm6UMUJa79H1fb0ElEX2X/VX/APrl4LPn7496kUR+fd/u7z7q/wAT88duakmL/Z+bpSfPUZwP744qQFvOvP36jCrjgfLweaZnzOz/AOD5GfL5f23SMR3Q5fG4tx+7PHWrJEZtpcw3RHmngFufm69elQ3DYv8ARs3IJJfjA5/dnmp94FrOWvQB5rDdgcfN0pIuV7R/4PdlI6jY/ZkzeTkfaOu05J3dOnSuH+D2o2p0zxMzSyqr6tdMMKc7fMb2616QXl8hcT24PnckjjG769a4D4K+cmja2wmt1LancucgnJMjZPXpU9UawcPZz0/HzXkd0uo2fnRHzp8lOBtbB+vvVeTUbJrZCZrnHndcNnOTWisk5ZP9JtcFckBTnPt83SoZHuCkeLm1z5oHCHpn/e60zCPJf/g/8A89+EOo2v8AYOqrJJcEx3tyvG7oJnGa7db60+0WOGuOY2x9/wBFrjvhE1wtn4mj+1Wo26veYBU8fv3/ANrpXdxtcGe0/wBItj+7bOEPPC9PmpLY6K7jzv0XX+76FE3dl9if5rvHmn+//epi3dkNY1Bt11n7PHn7/q9aRa4FqxNxa/fPO0/3v96oA851i+AuLYYt4sfIeOZOvzU7ERlG0t/v815DI72xK2mWu8kcff8ATvSfbrDZKd14AJOuX68e9Xkefy7cC6tckYOUPPHb5qQtcbZf9Ktc+YOdh46f7VPUz5o36/e+/oYjXll/bOogm85tY+hf/b96ureWRe0/4/c44+/6d+aerT/2zqINxb8W0XGw+r/7VXS0262/0iDn/YPzcdvmpI0qTjdb7Lr/AHfQzDeWgim+S+I8/nG/1HvUSXlsusag3lXxJhToGPY+9auZvKmzcQgicAHbwORx1qKN5Dq1+vnxACFMcdOvPWmKM42l6d33XkV01C2aS1Kwah904+Vv15qCS9g+zP8A6NqBH2oH7rdd4961ldy1rm7i5U54+/x9agkc/Zm/0tc/alGcDpvHFAoyjdafi+78jPtr6Ftavx9k1DJjTPyN0x9anhvIQLEiz1AnYQvyH0781Lbsf7b1AG64ESdAOPepoHGyxH20nKH+783H0pK5U2u3RdX/AC+hUe+gEDf6DqJHn5OIznO761DDexf23qBNjfFmiTP7vt+daO8eS5bUH/12M4Xj5unSq0DJ/b18Ptrg+Sn93j36U2EWrS06efdeRGt7GG07bp9+QqNt/d9PlHvTGu4vsdwv9majgyEnEXv9auqy+bYYvpDlG/u8/KPao2dDZ3OdSl/1jdk45/3aBprTT8+78ilHeJ/wkN239mahzaoD+76/M/vVhLuLybX/AIlOo8EY/d9OO/zU4Ff7fuf+JhKCLRMn5OPnf/ZqeJlMFpjU5TkjnCc8f7tJXHNrTTour7FR7iBorhTpOokFwSPL5PA/2qr/AGmH+3pm/srUCTaqOI/9pv8AarWbaEuN2pSgbxk4TjgcfdqvuX+3pR9vkH+irxhf7zf7NNihNWenTvLyGC4h/wBHxpGocH+504P+1ULzp5V2BpN9zKCPl6/d961F2hLY/wBoSkE4BIT5uD/s1FOV8i7/ANLkGJRk4Xj7vtRr3JjNX2/GXcz/ALQDrob+yb3HkEZwP7w96dbz4trMDSrs4c8cDH3vernynxCv+mSFvsx+XC4+8PamwtH9nsf9Nlx5hAOBzw3Xikr9ynJWWnRfzdmQtOxF6P7IuQGHOSPm4+tRJPINdiI0qcf6KQCWH95a0ZWTytQH2qQ4Xk8fLwfaoBJGdfgAuJCfsjcY/wBpeelP5ijLf3ej/m7IjEsvlQ7dEl4kztLj5felllnMd5jRWwynJ3r8/FWVa3EEWLycjzeGPUnPQ8U6VoNl6DcT42/N1+XjtxR8yedX+H/0rv6mcJroa/EV0nH+iEf61ePmHtUhkufssX/EmUDzVwPNXj5uvSpjJCNeg/fSc2hA68/MKd5tsLSEefLjzlweeTu6VKKcvh9zt/N5+YzzbvN2Bo8ZzjI85fn+X6VW8y7Osw50eIN9nI/1y4Az9Kv+bbF7zM8wzjON3Hy9qrNNbf23b/v5ubY4+9zzVBB7+50/vdvUbm7MUIGh26ASA4M68c9fu0E3pF5nRbY5I6zrz8o/2as7rUQQ4uJ8eYOct1zTJJbXy77NxP1GeW4+UUWBS1+H/wBK7rzKU32z+2bT/iS2o/cv/wAt19v9mp1F6EQDQrQjzDx568cn/Yod7b+2rIieY/uX5Jb2qxG1qYUzcXGPNbBy3XcaVipy0j7vT+93f94hZb3E/wDxI7Prx+/Xngf7FQSLd/2xbE6LaD9y/wDy3Xjlf9mtJ2tgtwTPPjjPLccdqrO8H9u2WJZifIfAJPqtDRMJ7+70f83b1KiJefZ4ANFss+cTgzr6t/s0+Rbzdff8SayGYx/y3Hof9mrQa3+zWo82bb55wefVqkm8nOo/vJifKGeT6N0osN1Nfh/9K7+plgXv9qWH/Ens8fZ3/wCWw/2P9mrKrfCBsaPY5EoOPOGOo/2akQxHWNLw02fsr464/gqbMP2WTIuNv2geuc7h+lNDnU+H3fz7vzIpBqBa4/4lVkAUwpMwOeD1+WqjjUBq2n50yyBETg4l6dP9mtWcQia83Lcn90C2CcYwenNVT5P9q6ZtjueYn25J6cdeaCadT+70fft6hJ/aP2Y506zDeauB5vGNw56UpbU/OuNtjZ42jBMvt9KnkERtz+5usecvBJzncPfpTmEfn3X7m4J2KDgnnjtzQRzqz91fj5eZmXB1L7XpBa0swwZ+kh4Pln2qZm1f7LKFs7Fj5pODIcY3fTrTZxH9t0UiC6GC+ASf+eZ681Owi+xzD7LeEea2QCc53dfvdKk1lJWj7q/pvzJWjXyB/oCt+/6YX+91rhPgsu7wzeFrNZA91K2cDkFzxW7rviOy0jQ570z6rdiKXPk21uWkc7ugG2ud+EV5b2vhSEXMmo2U7Rq8kEsB3IxGTkbOtF1cqNKpyT91/dLuj0VI1DRAacgBTrhePamGNPLT/iXoP3vTC+vWqUerWO6H/T7zlOB5Len+5TW1Sy8lSL+9x53XyWz1/wBzpVXRiqNW/wAL+6Rx3wmVjdeM0ksVbZrFwBwvALE7f1r0GNFWW1xYopKHkAfLwK8c8OeLNP8ACPivxpa6rHrqpdX/ANpt5rexklWVGQc8KcHOfSuib4s+GYpLaSaXxBHEqHMkmlyhQMDr8lTF2ReIUnP5Lv8AynfFFazbNin+sPBA/vVAsYGuah/oSY+yxEHA55kryG58aeMvFry/8IUi6XoMc7L/AGjqULtJOOCCkWwYGTjk81YtviDrvhrW7628a6TqN8Ps8Y/tHRbYvCEBf5nRgCh57Zo5ilRqKMnb8+6PYIolK2ZNkgz1OB8vFKYh5c2LJCfNGBgc9Oa4K2+MHgIwWZ/4SuAYUFlbIIyMfMNuc57VJL8WvAKieJvFVvkyg5VifToQMYp867mHsqjez/HudikY/tnUM2qY+zx4bA5+/wAVd2Za2zbRjGfT5eO1ee2fxQ8D3esXzQeKLV91sigtKEU43ZAzjnkUy6+MngG3nhjbX3cxfKWhikkUEjoWVSCfoaFJdyqlKejs9l37HfTHyrW6kaCPak247iACARz0rkPhf4xt/Hlhd6zp9gIom/cFXcElkJHp0Nch4z+LXg+88FeIbbSdXkm1SVHS3ttskcjyNhVADAHqRx1rN+FUuk/DmfxNpery3VrZw20OorvRl2o6/vCB7NgfjS5tdDWFF8krrX5+Xme5RrMTak2cIwpz8/3eO3FRMJvs74tYf+PpTjf/ALY56V5pH8afArG2jspNZvZ0XmG3sp2cAjqQQKJfi54Sa3Mdta+ILqd7pSII7CfcTvH94AfhmhyMVHXb+r+p6Tbib+3b/wDcRYMcfO/r+lS2/nCOxJtoAdmP9ZyPl7cV4xq/jfxVq2p3lv4L8D6nC8sYU3urs0SxAfxbFJJ9uas+H/h3Dd/YLrxpq3iPX7ySM4j3vbwQjGcIqMD+JNCfY1lRco81ui/9J9T2EC4aJx9mt/8AWZ+/15+lVIPtP9u3v+jQ8wp/y06/+O15MLPXvAt07aDZax4i8MyzMp02ViJrM5yCkhb5lzxg/nWlZ+Or+PW71774e+KIUNuvERWVvxG8YB9afML2fIpXXT9V5npqG5EtgGtoAQrZxJ0+Uf7NJILgWdwBawDLt/y09/8Adrz2y8dvJHpxuPAXjGGQq2EWJWHTsfNH61T8QeN7+48OanFofgfxWupvuSB7iFVjRyeCx804A69DRchRV1p/V35npSG4/wCEiuc28P8Ax6R/8tOvzv8A7NWY/tAgtMW8HUZ+fpx24rwLR/B/xI03UrnUf+Epub7WmsU3215akwMDn5PlkGMEHDDrnpXQ6T8QL7w9pVlB8QvDGrwXcbcXunxPNbyr6gBsqcY4NJPuaVKNkn6fl/iPXJBctFdAQQBi4xl89l68VDif+33xFDg2q9W77m9q8ol+Ongnybpbe1124Z5Btjjs5MvwOeSPSll+OHg2LVnu57bXI7UW4jad7KRVByflPPvT5kRGno1bp/l5nsIFxttwYoMg/N83Tg9OKjm8/wAm54h/1gxk8fw9a8qtfjR4WvFtl03RfE19KCCkcFg5OT05LAc/WrsfxHa7XUEg8A+MWaOUCQPaxqA3HHMnX6Zp3RmoWe39X9SP45eNdT8EPol3p/keZc3ccDgruzHkl8+2B1r0Wwllm0/Tpla3KyNuBA4wQxGK8I1jWbL4seP7W20bS9Qe00rTboXkcyCN47iRWjRGBOAQcnOa2fCfxQsbPw54U0UaDq2o65teF7O2RC6NCCrlssMdR161CZvOn+7Vlqlrt5+Z7JN9o2X2JIB8vy/L7HrzUGZ/7egBmg/49G/gOfvL71xEvje/Zb8f8K88S4K90h54PX95xVCXxj4om8Q250v4aXr7bQj/AE29jt/4l6YDA4ptmUFv6Pt2PTWe48hWa4tRiTk7TjGf96sK98ZaLbatLpVx4k0aK/lTdFA7gMeP97H4V5jeeH/H/jaSC38W2g0Pw2sgMthpMgaa4+bo8hOVH0rrl+HnhCHTdSs4vA0YjlTaXZVeQ/KcEOzFlI9QaLsr2Nu3/kvf1O1Y3X9vRYubbBtTn92efmHT5qkc3TW0ZN1ak+avIjP97/eryay0Pxb4L1+FfDNrP4g0lrdgun6rcJHJbZYHKzc7hnjBHStb+3fH/wBmiUfDmwXEoPOrr/e9PL/WhMc4WcUrdO3meig3W+7xdWoIxjMZ4+X/AHqrsbr+2rb/AEq2wYGz+7PPP+9XCr4o8ZQTXgvvhrv3AEG01KOQfd6HKj9Kxda1/wCIl9J9m03wFDp13c27RW1w9+kggBOC7jaOQOQKdyYLVry8ux66HujFGftdq37zBIjPPPT71Ixutt5/pNsMHj92ePlH+1Xilr8MvEPhnSLK68IXl+NejdTcJf3AktLp8/M7ocspPsa0rv4l6p4VS7tPH/hWSK9ljDwy6WGuIpztAK8D5WyM4J70ubuP2LT0a/8AJe/qeqym4/teyBubc5ifgRn25+9ViMziJT9pt+ZGGfLPPzHj71ePP8Y7YalayP4F8VRyRxOChsfmPTpzyP8AGp4fjd4d+xI0ukarG4kZvKaxl3Kdx44TGfxo5kOVCbjHb/yXu/M9bkM4W4/0qAYH9z7vHf5qqyGY63Yj7TCQbd8jZ97leeteVn40QSpO8fgLxS8bgfN9i4I9TTR8UtVuNb0xrL4a+I3LQOQJEWMlOPmGfTHQ460OS/pCjRlDV22f8vYv/GfxlqPhS28I/wBmXsIku9YVJzsyDBkh889BuWvS5Hctfn7VEV8oEcfd4PvXgWpy6h8Xb2NLDwpeadaaVBcxbtQ/c+ZcylSgHH8Jj5PvW1ofxVuni/sSDwffajrttZBL6G1kQmBo8oS5IGMnkD0NLm11LdHS6av/ANu9z13L/wBq6YftMf8Ax7Pxt6/c561Ixk+zSYvUz54+bA6bhx1rzMePfEv9pWDf8Kz1gssDhQZ4ssPl5Hpj+tOuPFXxCm0aSew+HEED/aA/l3GpoXKhhldgQcnpnPGapSIlFrl/4HdnqMrEzXQW7VcIOCB8nB5rLmv7VNY0yN9Xtt7I4Cl0BfgdBmvL9W0n4l+Pnkjv7Wz8L6DPsM9nFc7ryVBnKmULgZ+lWZfgx4WW4tIR4WiV5YmVpv7VnLqQOGDHoQeeBSbfQdKmrXutv7vY9YmfNucXwyJlGfl4+YcU4sPOuv8ATQvyrx8vHHWvLtLsfid4bs2tVt9E8Q2Ec48prq4MV0U3DAZgm0445xmtltb8fb7j/ihNLJ2DH/E4HXH/AFy5p3MpRUbrT8PI6m5I+26Kftufmfn5ef3bVMz/AOiT/wDEy2nzWGfl4+bp0rhJtX8eG60ct4I0pHDPx/awwT5Z/wCmXHH1rI12X4o6/G2k2Ghab4cQzNJPqi3S3GUB+4ilB8xPfFSma2T5V/l/Mz1oi78hctDnz+wPTfUVr9q/tLUsNEPuYyDj7tN8mMW64spR/pHTcP7/AF+9UdtBH/aOpf6HKeE/iHPy9PvVZmkrS/4HdeZoR/as2+Xhxs+bg8nFI32kRLl4d3m9cHpnpUUUa7rX/Q5PuHncPl4+tQ3lpFPYSQyWEjRu5DIHwSMnnOaDOyuv+B5+ZJAbj+1NRCvH91Cox0OKnHnebahnjOY23cfe4HTmvlrwVbE/C34uGRrxntZ50hma5YvGI87BnOeP1r274L20cPw38HssEztNYLM8ssm9izKrM2Se5PTtUpmlSKT+S7fy+p2bGUWEn72IYkIBA4A3dOtRAyf23qH7yPH2SLAx0+aTrzT2TFlIBZ/8tD8u4c/N1qEIf7cvyLZc/ZIucjn5pKpija0v+B3iYreBvDE01pPPoOhvM7+Y7GzQl2K8n3qT/hDPDsWm3VlDo2iR2zS8xm0Tbg7cg+9dBGpVLHFsnbnP3PlpkqM0N1/oyOfOBC56/d5oJUnzb/l3ORfwB4Ul1i8jk0DQSgtkIX7GgwfmGf0rc0vQdJ0m1tbTTbTSrW2DbzFFbqFZsfe69ferQEn9vXn+ioVNqnzbuvLcdKsxiTFr/okQ4PG77vH0oLqN6a9F27GNfaDo97K91eWmky3UV2ssc0lshdGDLg7uuawfG/gTRPG2vKdbuSGtYkKmGTZuXdko/PzKSASPYV2RWTyZ/wDRISftA4LdeV56UyNX/ty4/wBDh/1K8lhzyfakXCVlJrt5eQ2zjhtxamK6skOwKSEUFgBgc5p0kx8hv+Jhbf8AHwvO0f3xx96pYY5StsTY2/Q5+YfLx24pkkTiFv8AQYM+evccjeOelNkXXNr+ncihlf8Ati7b7fbbTEnGBx7/AHqW2lPlacP7Qtj8v90c/L/vUsKP/bV0PscGPKXuOT+VPtY28rTt1nADt9Rx8v0pIqTX4Lt2YjSube4/4mVuB5h52jjnp96oYJW/4SG8zewf8e6cbenJ561aeOT7PcYsoM7zgZHPv0qGJW/4SC7AtYcfZ0Oc8nk8dKphFq0vTy8iWOUl7HN7AflPb73A96bNKwsbotexH5zzgfLz061KkbmSyJtoQcHdg9OPpSSJL9juf9Gg++cc9RnqeKCLq6/4HdkPmY8RXP8ApMY/0NOMdPnfnrT4pP8AR7E/blI3DoB83HSmAS/8JFcfuYsfY053d978dKmUTC3sMQQ/eG7npwenFShytp6Lt2IW8lY77F2i/vB8yqvy/KtR3CQz648U86uj2gDRuqsp+Y84IxVpkn8u9Agt8mQYBPB+VevFNAn/ALdzshz9mx1P976UwTVn6eXZCxPHFDaKL1gu7aMKAG68dKSaVBFdH7ZIP3g5A+5932qygudkW6O3yGOeTx16cVHKLry7gCODlxt5PPTrxQQmub/hu/oZsFpY2niSSS2byZriEyTGOMAytkfMx28nHrWHovg3w3pOuv4jsVlh1a/crPcgkmT73GCMDOBnA7V1Lfav7ejOyHb9nbncf7w9qSD7YLezAjtyRIc/MfRvakbc7UVr0XVefkQyvEUvyL+5Py88fd4P+zUO6M69bj7fc5+ytxgYPzL/ALNX5vtmy9zHb8px8x/un2qL/Sv7btyVg/49Xz8x/vL7UCjJa+j7dvQQyQGEf8TC7x5g5xznPT7tOeSDFxm/ueF+bgfLx/u1MTeLB8yW4Pmj+I9Nw9qkb7VuuPlg+6MfMfTvxVGd1/TXl5GcTGdZixe3PNs2OByNw/2alLRrbRf6dckecvJHJO7p92pGNx/b0GVh/wCPds8n+8OnFTObj7PHuEOfNXoT03fTrSRUpL3fl28/IrFow97m9ue2eBx8vb5aiIQ6xZkXdwT5DY4HI/Kr5M++92mIdMZPT5e9VnM39s2HzRbTA+R3J9R7UBCW/p5dvQkQx+RHm7uSPN4OOSc/7tNm8r/TQ1zPzjcMcD5R04qwGnMKHzIM+bgnsRuPH1pspm23m2WAdMZHT5R15pkJ6/13XkU5GQa5p6i4uGYxSYB6H7vtU0YiFtGWnuNvntjjOTuPtTJmm/tnT8zQY8qTIA7/AC89amjklFun+k24YzNk7cgjcfekmXL4Y/11l5BO8K/ayZrjO0ZAz8v04qvuiOtacd0xP2d8Zzz93rVx3l8ycfarcfKMfL069eaqSO/9sWP+lW/+ofjb1+770MVPr6P8vQf+4MFvlpyPP4zuznLVnx6Lo9jquu6haWQh1C8iBuZ0QhpMK2MmtDzZTFH/AKdbZ8087B6nj71JPLIReAX1txH/AHOnB/2qBq99/wA+/oV90H9raVkTkm2fHDf7FPIthazYW4x9oH97+8tRmWX+0tN/0+1H+jvn5Ov3P9qpTLKIJd2o2v8ArxzsH94f7VJGjXw6/n3fkSuLU3N0GW4/1Yz9/wB6pSfZBqOk7UuMbHx970q+JZTcTYv7UDYv8HTr/tVUlll+36b/AMTC1PD5+Qc/L/vUxU7336ef8voTMtn5EmEuMecM/f67hTiLPzbkbbnOwZ+/0xT2lm8tidQtf9YAD5fTkcfep5klEk3+nW3CjjZ04/3qDO77/i/LyM2dLb7Zou1bjG5+u/8A55tUrR2gs7n5Lj/XNnl+u6knkk+26OWvbdjvfonX923+1VoySfZZz9utwBI3Ozp83T71CNZSdo6/n/M/Iq/2lZm2TF67D7SOdp/v9OlMg1KzGpamTeSKCE6IePl6jir4SX7OoPkg/ac8Dj7/APOkgEp1PUcGEHCYyP8AZ70tSU6dpafiu68iCHU7L/RCbuY4Q4HlthuB14qvd6xYJp8zLdXb7XJASNtxOfujitWET/6HlosbDnC+w6UFJ/Ibc8GfM/u8Yz/OjUlSpp7P7/N/3T5l8I2eq2/w8+Kljd6VqUOoanLNLa27J80olJx0447+3SvWvhHdLa/D/wAK2mpC/sr21sxBJBJGxOVAHYEY4yK7iFZf7Z1DEkXMSYyvI69asxpMHtcyxYCHOF68DpzSStqaVKlPs9l1/u/4TKk1GwFrIGu7wjzCc+U/HzdPu1GNSsjrl+3n3XNpHx5L8fNJn+H6VrSLc/ZX/fw58zg7OMbvrVbE/wDbt8POix9ki42c/ek96YRlTalv9/mv7pBHqliVsgLi8JGMfuZOfl/3abJqliIrvM16B5wyRBJwfl4+7WiguNln/pEPb+Dr8p6c0h+0bLrE8IIlGCU4HC9eaaJvTv1+/wA/8Jkf2hZf25dZmvgTbJ0gk9W7baki1CxxaET6l0OP9Hl9P9yrgW4/t64AniH+jLj5Pc+9WYRdbbX/AEmEj+L5Ov05pdC5zp6b7Lr5f4THOo2PkXGZdRwbgZ/0eX+8v+xT4720/tuc+ZqGTCv/ACwk9fTbWi/neTcHz4hi4GPk6fMvvTYfPOvzqZoyogXjZ05+tAKULS327+n90pwX1p5Vn+81HocfuZPQ9flpjahaGKTDanxcL/yxk67h/s1r2/mtDaHz09SNv3uD702cusL5uYwfOXnA4+YcdabI54c2z+/z/wAJkW19bDXrzB1Ekwp1hf8A+Jp8F/bhNN+XUCQpx+5c/wAP0q/E7f25dDz4wvkqQuORz160tuzNHpo+0RscHOB975frSRUpw7dF1/uvyKD31ubS7Hl6kRvOf3TZz+VRxXsI168Yw35zbrn903qa05ZHW1uj9tiUhzgkDj261HHJ/wAT+5H2qPH2ZcDj5fmPPWmEZRtLTp3fl5FaG/t9tgUttQwAQv7ts9O9MlvbcWN1iz1BgZDuyh65rTR8rZ4vo+nXj5+PrUcso+zXI+3xj5zz8vy+3WgSlG60/F9/QzPtkQ8RXB+w3xzZrxsP99/epReRCCw26ffffGMp7H3qYTJ/wkVx/p0Q/wBDTuOPnfmpBMv2ex/4mMR+ZcnK88H3pFya006Lq+3oVJLmFotQzpt/gyDPy/7K/wC1TfMiOvg/2ZeZNtjt/e/3quNPHsvv+JlEP3g5yvHyr700zp/bqn+0IsfZj3X+99aAjLR2XTz7IiSeERW5/si+5chcY46/7VE7xCKfOkXuNwzyvPT/AG6uRzp5cX/EziJ3nnK89feiSZNs3/Ezi+8O6/L096diOd8234y7mY7x/wDCQRD+yL3P2ducr/eH+3SRGLyLL/iTXhBkPdeOG/26utMv9vwn+0IsfZ2+XK8/MvvT7eRRb2mdQj/1h5yvP3vekjRzaitOneXmUpPKK3//ABJrwHZ3ZeflP+3Ue5RrltjR7zi1bHzL/eX/AG61ZZF8u+/05D8nbHy8Gmeav9uWo+1qf9Ffjjn5lpu5Mar106PrLsUm2/ZR/wASS7/1wO3ev94f7VTb8G626NdZKj+Jfm4/3qtiVPso/wBNB/fr82Rz844qR3QveZvNoCDOCPk46inqQ6j7f+leRkMf+JzZuNKuciBuNy8c/wC9U/nP9ljA0e4UecpwXXg7uv3qmMif2xZKLp2zA+Md/epS0Zt4z9rmYeeozjqd3TpS1KlP4br/ANK7vzK3mOZL/wD4lM5yF/jXn5f96oHkcatp5/smXIhbHzrxx061otJHv1AefONoGcA/L8vbiqzlP7W04+fcnML8EHnjr060XCEt9Onn/L6iedL9nRV0abaJs43px8x560+SebZeEaRJk4zl0+bge9ThohAv+k3ZBlPzBT13HjpSM8ZN4PtF3lcZG0/LwOnFDI5tfh/9K7rzKc00y6xp+NKYHypOd6ccLx1qWGScWyY0k585uN68fMeetNnMY1fTgJ7w5jk6q3PC+1SxPF5Cn7Re481uQrc/Mf8AZpJlyfux93/0rvLzB57nzbn/AIlBJ2D/AJaJ83X3qq0tx/a+nH+y8HyH/jXj7tXHeHzJ/wDSb4YQE4VuOvT5ap7oW1TT/wDSL7cYXx8rf7P+zTewU+vu9H/N29SVJbjyYv8AiTj/AFx43p6nmieS4Bvj/ZI/1XXevPBp26ExR7brUMeaRna2ep/2aWYxA3uLi+ysXOVbA4P+zRYOvw/+ld15lQyXX9p6ZjSVI+zvnLr/ALFPL3BtZs6Qv/HwON6/3lo/d/2lpv8ApF9zbvj5W5+5/s1KREbWUi4vseeOSGz95f8AZpItv4fd/wDSu78yXzLoXNxt0mM/IuP3i89etUppbv8AtDSydJjUkOMeYvHymtRVj+0zjz7vOxcjB469OKoT+X/aOkYmuz9/BIP9w+1OxFOSu/d6P+b+V+ZK0l6YZP8AiURZEowPNXnkc9Kk8y982U/2VDjYOfNHJ9OlS/u/Il/e3ePO5OGznI6cdKkPl+fNl7rIQZ4bH4cU7Gbkv5fz8vMyLqS+F5pH/EsgB3vx5o4/dn2qdpL/AOyzhdLtz+9brKOfm69KfcNGLzRgPtJ+d8ZVuP3bdeKnkERtJ8/aMeaxOAeuaSRpKatH3fz7vzGlVFso+xuP9KzjK/3+vWmwIp1XUW+xOSyoCcrz8vTrUX26xMAH29zi4/vf7fT6VHBf2H9p3/8Ap7j5U/i6cdqkFCdpaP7n3ReiVQbL/Qn4QgHK8cD3oZEFvIBpshG8nG5fXr1qpFfWIaxH9oOTsP8AGeflFL9usPIlP9pTEBzyHOevSnoS6c77P7n3YsS/8Te+P9myHMSfxJz1/wBqrCqu+1zpkgIU4+ZPl4H+1VCK8sv7bvf+JhLjyE/iPHLdKnF7YM1s39ozcg/xnngdeKEVOE77PZfzdvUlcA20i/2VIRv6bk556/eqvsX+3b0/2c5zaR90/vSf7X+cUyS+077NN/xM7j/Wcnecjn6VCL2xGuXf+nz4+yJ3P95/ahtFxhO0tH90u68zRRF2WedMfj/aT5eP96mMimO7H9mSf60HG5Ofu/7VQrfWPl2WNQucEjueeD14pj3tk0N5i+uRiYdCwP8AD04p3JUJ32f/AJN39SZVU67MP7Of/j2Xunqf9qp4UUJa40xx17p8vX3rNW+sv+Ehl/0y6x9mXoG9T7VPBqFh5doftd4eTj5X569eKSasOdOdl7r2XR9n5liSMfZ7gfYCf9IBxlefmX3pIgR4gnxY4Bt15yvPP1qo+pWJhuv9IvuJwTiN+PmXpxSw31kNfmImvSxgXI8qQ9/pRdAqdS0rxez6PyLtsH8qxIsV75+YccGpJY2+zy/6EhJmXC5HzfMOazrbULFYLDMt/nnA8qQ9j14pXv7IwzESah/rwSfJk9R7U7kulU5vhf3Pv6l2BGGvXJ+zoB5C85689Kktw4TTcQRrwc4P3fl7VnRX9p/b1yf9OJ8hf+WMnr9KfBf2oXS8LfHAOP8AR5efk/3eaQp0p/yvZdH/ACs0JlkNpeYt4T8zcE9fc8VCiyDxFPiGHm1X5t3J+Y8HiqkuoWf2O9BTUSC5z/o8uc/981Et9af8JHOdmoZNooI+zS/3j225obHGjO0vdez6PyNmIXAS1/0e3GBzhj8vHbiopFufs9zi3t8lyQNx+b3PFU4r2yMVrti1PaDx/o03p3+WmyXlk0N1mPU8b+f9Gm9v9mmQqU7/AAv7n39Swon/AOEimPkwf8eic7j/AH39qlAufKtP3FtjcP4jxx9KyzeWv/CQSkxajg2iji2m/vN/s5p63VmILH9xqfDjGbeXjg+1JNGkqUtPdey6Pt6l91utl7i3tTlxwWPPyr7UhW4/tuM+Rb/8e55DH+8PaqEl3aeVfjyNTwZBn9xL/dX2pGurb+3YSLfUv+PdhnyZPUe1F0CpSt8PR9PJeZsQi58qPNvag7jkbjxyenFEguQJsQWx5G35jz068Vmw3Vv9ntx9l1L/AFhx+6fI5PWnyXEOLr/QtRIJBPyNz9Kq5m6T5tv6v6lkrN/b8JMUGPs7dzn7y+1PtlnEFqGhgz5h4BPAw3tWd9qT+3oXFnf8WzclD6rTobpTb2uNOv8ACykgben3uetK5UqUuVadP8/M05hKEvSI4eUOOevynrxUB8/+27X5IQPsz55OfvJ04qvLdArf/wDEuveUwSV+9wfeq7XIGuWf/Esu/wDj1cA4HHK+9JsUKT106Pt29TXYT/ZANkIfzl47Y3j2qQrMZrnaIsEDGc56d6yPtP8AooA0q7AE69cf3h71L55ae8J0q5PyjdkqN3H1pkuk1f8A4Hl5lhxKNXsc+X/qXDY/DpViRbjyEBMRYSqTgHGN386xGnY6tp5GkXAxC4GWTgf99VPI7fZlU6HPtEwON8fXd1+9SuVKk/d2/Du/M0WFzvvNphHTGQf7veq8ouP7V03LR48t88HrgVVaRi99nQ5z0z88fPy/71VpS51bTT/Yko/dPj95H6D/AGqLlQpa7rZ/y/y+puot2YvleEHzCeh6bjRIl1i4w8PPTg+lZaFzEM6DL/rT/wAtI/7x5+9Sy7m+0Z0CU8dfMi+bj/ep3Rn7LXdf+S9/UtXC3X9r6eS8X+rlzweeFqaFbsW4G+Hd5rc4PTcax5lI1WwI0KRT5cn/AC0j9F/2qkQP5CD+wX/1zcebH/eP+1STRpKl7sdV/wCS935mwwuvNnw0WPLG3g8HmqLLc/2tppLxYEEmRg/7OahkV/NuP+JE5HljH7yPnr/tVVBlGp6af7EZSIXx+9T/AGfei6FTp76rZ/y9vU2wt1sUGSHcJeuD054pZ1nxdkvHtMXHHTg1m4m8kY0Pnzc7TMnvz1pszXObzGh8GPr5yc8H3qron2V3uvvj3XmW/wB//aemZkix5EmRjk/cp7mcWs254932hecdt61mbrgajppGjgEQOP8AWpx933qRmuRaS50hQfPU481P7y+9SrFun8Oq++Pd+Zs5l+13AEkYARcAjkdeaoOZDeaQWniY5fOB1+Q9KQSXX2y4xpQIMaj/AFq89aqM919p0knTI12l8fvV4+RuKZEKe+q27r+V+Zsb5PLl/wBKhB8zg46DI469aGdhPJ/pkIXYMLgZB9etU2mvRFMF0pCDJnHmr83I5p5kvjK5Glx8oOTKvPtQR7P0++PkRXUhF3pH+mQn53ycD5v3bdOasvKRazFb2EHzDzgcc9OtZ91Le/a9I/4l8SkO+F80cfuzVky3/wBnmxp8P+sPHmjnnrSRpKGkdvvj3ZOy3flD5LX/AFwPBP8Ae+nWo4Bd/wBp3xCWvKp1LZ6fSmtHb+Qv+gMMzjjZ/tdajgjt/wC1L8fYWPypzs68dKBJK0v66rzLMQu/9DJS14Q929B04qQi8EMny2n3j/ex1+lV4o7f/Qv9CIOw/wAA44FOaK2+zzE2LcMeNnXmmQ7X/ru/MbGLz+2rohbXJhTufVuvFWcXm6D5bTjPdv04qikVv/bd5/oRP+joT8nXlql2W/8AoYOntz0+T7vFBU0rr0X5epMReCGX5LTO/PVsduvHWqwF3/b11xbc2kfc/wB5/anNHbLb3BGnNjf93aPm6c1CI4Dr9ypsz/x5pztH95+KBxStLTp/l5l9ftQS0+W2z35PoenFRSfaBDd8W4/ejrnH8PWmiKDbZYsSMHgbR8vBqOWKI217iy5Mw+XA5+7zQTFK/wDXf1HL9q/4SF8C3A+zDuc/eqxb/aRDbfPbnk5Izg9elUxGg8QttsePswGeOfmqa3iTybUjThwx4+X5etC2HNKy9F27PzHSmcxT7JoB+/HOOnK9abGJv+EglzNFj7OOAvPWmtGPLuQNPBBnB6r83K0IoGvyH7GM/Zx82V9aTBWs/R9vIkthL9nscXMffPyjng9Kc5fy5cXcYPmj+EcciorYMILDFiAAf7y/L8pp7k7JwNOBHmDI3L83I5pia97/AIbuRR7xr04+1JjyF42jjmnRl8ab/pacg5+Uc/JUUZf/AISCf/QR/wAe687l9elPj3Y0/On4wDgbl4+WkXJbbbLt2Y6QyC2uz/aEeAW/gXioE8z/AISSb/TkI+yLxsXj5zUkgc2l7/xLRklv405qJA//AAkkrf2eObRR95efnNDHHaW2z/l8i5GZNlvjUIyCf7i801/MMVz/AMTGMYbrsX5eBSRBxFbf8S1fvf304p0gYw3AGnLnd03L83TmqM+vT/yXuV18wa9Mv21dxtFOdi/32qYeYIbPOoIcsBnYvzcGoSD/AMJE+LNT/og4yv8Afap9reVZZsVBDj+Jfl4PNIqXTbZduw1hII74m9X/AFg52Dj5Vocv/bsA+2Lk27HbtHqOaV1by9Q/0RcGQY+YfN8q05gTrdvm2UfuHwcjPVeKBJ/k+3ZDoy3kQE3y8yHDbV+bk8VJIxCz5vlB47D5KbAHEEIFtFnzDnJHHJ6VK6S/6RiGHkDbz9760zNtX/4buVGkH9u24+2Ln7O3yjHzcrzSo6i3tv8ATx/rD83y89eKcyzf27A3lxBBbtk55B3LUipdCKEeXb5D8jnAHNIptWXp5efkRyyoUvsXyn5PUfJwahd4xrlnm8AP2VxtyPm5XmrU4udl5tSDlDg888HrUDC6/tm1O23/AOPZ89cj5l6UmOFvwfbt6CmSIWn/AB/DHnj5tw/vjin+bAZ7sfbQDtXPzD5eKRhdC2AK2o/fL0zj74qRPtnn3GFtui4Pzc8d6BO1n/wPLyKDyQHVdP8A9OyfKfA3D5uKsvNbGFf+JgOJhzvHXd0qOYXv9o6eSLXO1+m70qywv/LGRaA+YP73TdTKk17uv4ru/IrtLb770/2jjgdHHHy1VmkgGq6Wf7QJPlyfxj+71rQxe7rvi17f3v7veq1x9s/tPSyRbZ2yf3v7opFQav8AJ9v5fQfHLb/Zj/xM8fvm53j+8eKkkntibj/iYY4GfnHFSR/bTAeLXPmt13dNx/WpJPtZM3Fvjbxnd+tMzbV/+Cv8jPnkgOsaaRfFv3chHzjnhakjeE2yYvm/17c7hk/MadN9p/tbTtwg/wBXJnGfRelSr9oFsmDBu85uucffNCKk1yx/rrLyBni866/0tuIhn5hx16VT8yP+1dJAuWP7h+p68L1rRk8/zbjmEfuxjr/tdapnzv7S0r5o9vkvnA9l6UCpta+j/wDSfQmaSFYMm6lI877w65z0+lJM8RlvQJ5t3lZwM4Xg9KllF35RxLAGEnXaemf505xPuut8kZXy/lAXkcHrQQmt7/1deRnl4/7U0oebMT5D468/d60+VohaSnzLnH2hecNn7y1JJ5n9paZiRB+5fI29fu9KdIJ/ssv75M+evO3tuWka3Xu/11fkP/di7uMtc58tegb36VQlMQudG+a6+84GQ39xutae2b7XcbZ1A2LgFeh5qjIJftOjh7hCS79F6/u2oJptX36f+2vyJ98Jhny14AJDkhXz17cdKkcxeY+WvPudAr4/DjrSqk/lz4uEU7zg7BxTyk/nHFyoGzpsH50zNtd/608jJufIa60k7r7h2xkPn/Vn2q0TC1vKM3/+sP8AC/r9OlMuxcC80nN3GSZGydg5+RulWWW5EEpF2g+c4Owcc9KSN5PSOv5935H/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The PR interval is 0.43 sec and the QRS duration is 0.11 sec. The markedly prolonged PR interval suggests slow conduction through the AV node, but the somewhat widened QRS also suggests infranodal conduction delay.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6416=[""].join("\n");
var outline_f6_17_6416=null;
var title_f6_17_6417="Hidradenitis suppurativa nodule and sinus tracts unroofed";
var content_f6_17_6417=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hidradenitis suppurativa nodule and sinus tracts unroofed",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the completely unroofed inflamed hidradenitis suppurativa nodule and multiple sinus tracts. Note the skin edges are beveled and the base is scraped clean of debris by rough gauze grattage. Hemostasis is controlled using ferric chloride and the wound is cleansed with hydrogen peroxide and covered with petrolatum dressing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6417=[""].join("\n");
var outline_f6_17_6417=null;
var title_f6_17_6418="Atopic dermatitis papular";
var content_f6_17_6418=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous erythematous papules are present on the hands of this patient with atopic dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6418=[""].join("\n");
var outline_f6_17_6418=null;
var title_f6_17_6419="Vitiligo focal leg";
var content_f6_17_6419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Focal vitiligo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Area depigmented by vitiligo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6419=[""].join("\n");
var outline_f6_17_6419=null;
var title_f6_17_6420="Alteplase: Patient drug information";
var content_f6_17_6420=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Alteplase: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     see \"Alteplase: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/2/12328?source=see_link\">",
"     see \"Alteplase: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Activase&reg;;",
"     </li>",
"     <li>",
"      Cathflo&reg; Activase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Activase&reg; rt-PA;",
"     </li>",
"     <li>",
"      Cathflo&reg; Activase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691474",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop heart muscle problems during a heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to clear blood clots out of catheters.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691756",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat blood clots.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701474",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to alteplase or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Aneurysm, arteriovenous malformations, bleeding problems, brain tumor, injury to the brain or spine in the last 2 months, stroke, surgery on the brain or spine in the last 2 months, or very high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697238",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had any recent surgery or dental care, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care to stop injury and avoid falls or crashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bleeding may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695992",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the catheter.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10945 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6420=[""].join("\n");
var outline_f6_17_6420=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132252\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132253\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012275\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012274\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012279\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012280\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012282\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012277\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012278\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012283\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012284\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=related_link\">",
"      Alteplase: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/2/12328?source=related_link\">",
"      Alteplase: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_17_6421="Ethotoin: Drug information";
var content_f6_17_6421=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethotoin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/20/9541?source=see_link\">",
"    see \"Ethotoin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Peganone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F168825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Hydantoin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F168816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Generalized tonic-clonic or complex-partial seizures: Oral: Initial dose: &le;1 g/day; usual maintenance dose: 2-3 g/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F168821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anticonvulsant: Children &ge;1 year: Oral: Maximum initial dose: 750 mg/day; usual maintenance dose: 0.5-1 g/day; maximum dose: 3 g/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F168817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15881396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in patients with hepatic abnormalities.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peganone&reg;: 250 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F168791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10380944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM217560.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM217560.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4303477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer after food to decrease GI distress. Administer in 4-6 divided doses daily, spaced as evenly as practical.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F168803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Generalized tonic-clonic or complex-partial seizures",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F168823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, dizziness, fatigue, fever, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Skin rash, Stevens-Johnson syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, gingival hyperplasia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Blood dyscrasias",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Diplopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Lymphadenopathy, systemic lupus erythematosus (SLE)-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F168805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic abnormalities; hematologic disorders",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F168794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Have been reported with use; patients with a previous history of adverse hematologic reaction to any drug may be at increased risk. Early detection of hematologic change is important; advise patients of early signs and symptoms including fever, sore throat, mouth ulcers, infections, easy bruising, petechial or purpuric hemorrhage. Discontinue therapy in patients with decreased blood counts. Hydantoin-like compounds may interfere with folic acid metabolism precipitating megaloblastic anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F168822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F168798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Anticonvulsants (Hydantoin) may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May increase the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Specifically, osteomalacia and rickets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Anticonvulsants (Hydantoin). Anticonvulsants (Hydantoin) may decrease the serum concentration of Chloramphenicol. Increased chloramphenicol concentrations have also been seen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Ethotoin may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Ethotoin.  Management: Anticoagulant dose adjustment will likely be necessary when ethotoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F168812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F168799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F168807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal ingestion of antiepileptic agents has been associated with neonatal coagulation defects/bleeding usually within 24 hours of birth. Congenital malformations (including a pattern of malformations termed the &ldquo;fetal hydantoin syndrome&rdquo; or &ldquo;fetal anticonvulsant syndrome&rdquo;) have been reported with the use of other hydantoin derivatives, however, case reports using ethotoin during pregnancy are few. Epilepsy itself, the number of medications, genetic factors, or a combination of these probably influence the teratogenicity of anticonvulsant therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to ethotoin during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F168818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F168808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer recommends discontinuing breast-feeding during ethotoin therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F168809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken after meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F168806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Peganone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $157.22",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4303479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC and urinalysis (initiation of therapy and monthly for several months); liver function tests if signs of dysfunction; suicidality (eg, suicidal thoughts, depression, behavioral changes)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F168810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Peganone (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4303470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stabilizes the seizure threshold and prevents the spread of seizure activity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4303472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 3-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine, feces, saliva (minimal)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8929 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6421=[""].join("\n");
var outline_f6_17_6421=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168814\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168825\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168816\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168821\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168817\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881396\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881397\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168802\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168791\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10380944\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303477\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168803\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168823\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168805\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168794\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168822\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168798\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168812\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168799\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168807\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168818\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168808\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168809\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168806\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303479\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168810\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303470\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303472\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8929\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8929|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/20/9541?source=related_link\">",
"      Ethotoin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_17_6422="Malignant mesothelioma III MRI";
var content_f6_17_6422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59885%7EPULM%2F74112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59885%7EPULM%2F74112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant mesothelioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI scan, coronal, T1 weighted sequence, shows circumferential encasement of the left lung with loss of volume and ipsilateral shift of the mediastinum to the left. The aortic arch and the descending aorta are encased by tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant mesothelioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI scan, sagittal T2 weighted sequence, shows large right sided pleural effusion layering dorsally in this recumbent patient. The diaphragm is intact. Above the lung apex, the right subclavian vein is seen in cross- section and forms a bright round signal. Behind it is the right subclavian artery forming a smaller circle. Above the vascular structures, the brachial plexus is seen in cross-section forming several less bright rounded structures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6422=[""].join("\n");
var outline_f6_17_6422=null;
var title_f6_17_6423="Pleomorphic calcifications";
var content_f6_17_6423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Pleomorphic calcifications (suspicious)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 573px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three different cases of pleomorphic calcifications seen in a segmental distribution in Panel A; faint, with some linear branching calcifications in Panels B and C.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6423=[""].join("\n");
var outline_f6_17_6423=null;
var title_f6_17_6424="Treatment and prevention of giardiasis";
var content_f6_17_6424=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of giardiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/17/6424/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/17/6424/contributors\">",
"     Flor M Munoz, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/17/6424/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/17/6424/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/17/6424/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/17/6424/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/17/6424/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/17/6424/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giardia lamblia (also known as G. duodenalis or G. intestinalis) is a flagellated protozoan parasite [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. G. lamblia causes both epidemic and sporadic disease and is an important etiology of waterborne and foodborne diarrhea, day-care center outbreaks, and diarrhea in international travelers and adoptees [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/1\">",
"     1",
"    </a>",
"    ]. The treatment and prevention of giardiasis will be reviewed here. The life cycle, epidemiology, clinical manifestations, and diagnosis of giardiasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive measures for the treatment of individuals with symptomatic giardiasis are largely related to correction of fluid and electrolyte abnormalities that result from the diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link\">",
"     \"Oral rehydration therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic patients with giardiasis should be treated with antimicrobial therapy. Symptoms include diarrhea, malaise, steatorrhea, abdominal cramps, bloating, flatulence, nausea, and, especially in young children, weight loss and failure to thrive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with giardiasis should be counseled to avoid lactose-containing foods for at least one month after therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/4\">",
"     4",
"    </a>",
"    ]. Acquired lactose intolerance occurs in up to 20 to 40 percent of cases and can take weeks or many months to resolve even after parasite clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment is not usually recommended for asymptomatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, treatment may be warranted to prevent the spread of infection if a patient is a household contact of a pregnant woman, an immunocompromised individual (especially in the setting of hypogammaglobulinemia), or a child in a day-care or other setting who might transmit infection to others [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs are available for the treatment of giardiasis (",
"    <a class=\"graphic graphic_table graphicRef61810 \" href=\"UTD.htm?34/16/35084\">",
"     table 1",
"    </a>",
"    ). In randomized trials",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systematic reviews, these drugs have been shown to relieve symptoms and eradicate Giardia with minimal side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/9\">",
"     9",
"    </a>",
"    ]. The data are discussed in the following sections.",
"   </p>",
"   <p>",
"    We favor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    as the drugs of choice for the treatment of giardiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. Alternatives include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    , furazolidone (no longer available in the United States), and quinacrine (not commercially available but compounded at some pharmacies).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H838437\">",
"    <span class=\"h3\">",
"     Nitroimidazoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitroimidazoles include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H838624\">",
"    <span class=\"h4\">",
"     Tinidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     Tinidazole",
"    </a>",
"    is highly effective for the treatment of giardiasis and is approved by the FDA for the treatment of giardiasis in patients older than three years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Tinidazole has a longer half-life than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and offers the advantage of a single-dose treatment. A single dose of tinidazole has efficacy &gt;90 percent with few associated side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/9,13-16\">",
"     9,13-16",
"    </a>",
"    ]. Tinidazole is available only in tablet form. For children unable to swallow tablets, a pharmacist may crush the tablets and mix them with flavored syrup; the syrup suspension should be shaken before use and is good for seven days at room temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/17\">",
"     17",
"    </a>",
"    ]. Side effects include metallic taste in the mouth, nausea, vomiting, headache, and disulfiram-like effects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/8,10,18\">",
"     8,10,18",
"    </a>",
"    ]. To minimize gastrointestinal side effects, tinidazole should be taken with food [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Metronidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    can be used in children and adults (although giardiasis is not a US Food and Drug Administration-approved indication for metronidazole). A five day course has efficacy of 75 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/6,13,18,20\">",
"     6,13,18,20",
"    </a>",
"    ]. Some compounding pharmacies can prepare a stable oral suspension for children who are not able to swallow tablets. Side effects include nausea, gastrointestinal discomfort, headache, and a metallic taste in the mouth; less commonly, dark urine, paresthesias, and dizziness occur [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/8\">",
"     8",
"    </a>",
"    ]. These side effects may occur in up to 27 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/13\">",
"     13",
"    </a>",
"    ]. Metronidazole may have a disulfiram-like effect, and alcohol consumption should be avoided. Isolates of Giardia with decreased susceptibility to metronidazole have been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Nitazoxanide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     Nitazoxanide",
"    </a>",
"    , a nitrothiazolyl-salicylamide derivative, has been approved by the FDA for the treatment of giardiasis in children older than one year [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/21\">",
"     21",
"    </a>",
"    ]. A number of head-to-head trials have shown nitazoxanide to be at least as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    in relieving symptoms in individuals with giardiasis, with efficacy ranging from 81 to 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/18,22-24\">",
"     18,22-24",
"    </a>",
"    ]. In addition, nitazoxanide is effective in treating multiple other intestinal parasites (eg, cryptosporidium and amebiasis) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/6,25-27\">",
"     6,25-27",
"    </a>",
"    ]. Nitazoxanide is available in liquid and tablet form [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/19\">",
"     19",
"    </a>",
"    ]. Side effects include nausea, anorexia, flatulence, increased appetite, enlarged salivary glands, yellow eyes, dysuria, and discolored (bright yellow) urine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Albendazole or mebendazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comparative clinical trials have demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    is at least as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    in the treatment of giardiasis when given for five days or more [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/13,18,28-30\">",
"     13,18,28-30",
"    </a>",
"    ]. Albendazole is also active against helminths and has fewer side effects than metronidazole and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    . Albendazole comes only in tablets, and should be taken with food to increase bioavailability [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     Mebendazole",
"    </a>",
"    has a cure rate of approximately 80 percent for giardiasis; some studies have reported efficacy as high as 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/13,31,32\">",
"     13,31,32",
"    </a>",
"    ]. It is also active against other parasites and is associated with fewer side effects than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/10,31-33\">",
"     10,31-33",
"    </a>",
"    ]. Mebendazole is not approved for the treatment of giardiasis in the United States. It comes in tablets and suspension, and should be taken with food to increase bioavailability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Paromomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     Paromomycin",
"    </a>",
"    is an aminoglycoside with activity against G. lamblia and Entamoeba. It is not approved in the United States for the treatment of giardiasis. In clinical studies, the reported range of efficacy for Giardia is 55 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/8\">",
"     8",
"    </a>",
"    ]. It has poor intestinal absorption and is a reasonable alternative for patients in whom other agents are contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Furazolidone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Furazolidone, a nitrofuran compound, is an alternative therapy for the treatment of giardiasis that is no longer available in the United States. Furazolidone is effective and well tolerated, although its efficacy is generally reported to be slightly lower than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (approximately 80 percent), and it must be administered four times per day [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/8,18,19,34\">",
"     8,18,19,34",
"    </a>",
"    ]. Side effects of furazolidone include gastrointestinal upset, headache, hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency, and neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/8,18\">",
"     8,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Quinacrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quinacrine, the first effective drug for giardiasis, is no longer distributed in the United States (although it is available from specific formulating pharmacies). Quinacrine may cause nausea, vomiting, dizziness, headache, yellow-orange discoloration of the skin and mucous membranes, and hemolysis in children with glucose-6-phosphate dehydrogenase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/8,18\">",
"     8,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consistently recommended therapy for giardiasis in pregnancy because of the potential for adverse drug effects to the fetus. When the disease is mild and hydration and nutrition can be maintained, therapy can be delayed at least until after the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/8\">",
"     8",
"    </a>",
"    ]. If treatment is necessary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    can be used as systemic absorption is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/8\">",
"     8",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    are alternative agents but should not be used during the first trimester.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with acute giardiasis who are appropriately treated, symptoms typically resolve within five to seven days, and parasites are cleared from the stool in three to five days [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/8\">",
"     8",
"    </a>",
"    ]. There is no need to repeat the stool examination to check for parasite clearance in individuals whose symptoms resolve.",
"   </p>",
"   <p>",
"    In patients with chronic or longer standing giardiasis, symptoms usually do not abate quickly. Reevaluation of stool specimens should be undertaken in patients who develop recurrent diarrhea after treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RECURRENCE OF SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent diarrhea following treatment may be due to residual lactose intolerance or other associated small bowel absorptive deficiencies, rather than recurrent infection or antimicrobial resistance. As a result, reevaluation of stool specimens should be undertaken before empiric retreatment is administered [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients should be counseled to avoid lactose-containing foods for one or more months after therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In some patients, poor weight gain and symptoms of bloating, diarrhea, and nausea may persist after treatment and documentation of negative stool samples. Residual duodenal inflammation has been identified in some of these patients, although the etiology is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent diarrhea and documented Giardia infection after initial therapy may be caused by reinfection or drug resistance. Potential sources of reinfection should be sought by reviewing the exposure history, risk factors, and hygiene practices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Either a second course of the original agent or a different treatment can be administered [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients who have been reinfected should have a clinical response to the original antigiardial drug. Treatment failures, clinical resistance, and in vitro drug resistance have been reported with commonly used antigiardial agents [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/13,37,38\">",
"     13,37,38",
"    </a>",
"    ]. This has resulted in active research for new drugs for the treatment of giardiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Options for treatment of refractory cases include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of a drug from a different class (eg, a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"       nitazoxanide",
"      </a>",
"      if the initial treatment was with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"       tinidazole",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/34,40,41\">",
"       34,40,41",
"      </a>",
"      ]. This approach is the most likely to be successful and is the safest in children. More than one switch to a different class of antigiardial agent may be necessary in some cases.",
"     </li>",
"     <li>",
"      Longer courses of the original agent (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      for 10 days instead of 5) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/9,42\">",
"       9,42",
"      </a>",
"      ]. However, reevaluation of symptoms during and after the prolonged course is necessary since the organism may be resistant to the original treatment.",
"     </li>",
"     <li>",
"      Higher doses of the original agent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/40\">",
"       40",
"      </a>",
"      ]. The dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      , for example, can be increased to 35",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. Although this option has been used in adults, it is not well studied in children in whom safety is a concern.",
"     </li>",
"     <li>",
"      Combination regimens may be necessary in patients with infection refractory to other alternative approaches and patients with underlying immunodeficiencies. Reported effective combinations include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       Albendazole",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day PO, maximum dose 400 mg) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      PO per day divided in three doses, with a maximum dose of 250 mg per dose) for five days; this combination has been reported to be highly efficacious in patients who have failed standard metronidazole therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/8,30,43,44\">",
"       8,30,43,44",
"      </a>",
"      ]. In a study of 38 adults with metronidazole refractory giardiasis treated during an outbreak,",
"      <span class=\"nowrap\">",
"       albendazole/metronidazole",
"      </span>",
"      for one week was effective in 79 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      PO per day divided in three doses, with a maximum dose of 250 mg per dose) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"       tinidazole",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      PO single dose, with a maximum dose of 2 g) plus quinacrine (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day PO divided in three doses; maximum dose 100 mg per day) for 14 to 21 days [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/46\">",
"       46",
"      </a>",
"      ]. In an adult study, three patients who had failed sequential",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"        albendazole",
"       </a>",
"       /metronidazole",
"      </span>",
"      combination and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"       paromomycin",
"      </a>",
"      therapy responded to a combination of metronidazole plus quinacrine administered for three weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/45\">",
"       45",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Combination therapy may be warranted in immunocompromised patients who have been unresponsive to other treatment strategies for refractory disease [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/6\">",
"       6",
"      </a>",
"      ]. In such patients, several different combinations or sequential approaches may be necessary for success. Consultation with a specialist in infectious diseases is suggested when combination therapy is being considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The possibility of underlying immunodeficiency (eg, hypogammaglobulinemia, IgA deficiency, HIV infection) should be considered in patients with either treatment refractory or repeated recurrences of giardiasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures include hygienic measures for infection control, outbreak investigation, and water treatment. No vaccine against Giardia lamblia is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Infection control",
"    </span>",
"    &nbsp;&mdash;&nbsp;To prevent transmission of Giardia to other patients and hospital staff, patients with Giardia infection who are in diapers or are incontinent should be placed on contact precautions for the duration of illness (in addition to standard precautions) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H10#H10\">",
"     \"General principles of infection control\", section on 'Isolation precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Attention to hygiene is necessary to prevent person-to-person transmission of giardiasis. Strict hand-washing, care with diaper disposal, and treatment of symptomatic children can prevent the spread of giardiasis in day care centers. Hand sanitizer is effective against trophozoites passed in the stool but not against the cyst form that survives in the environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Outbreaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The local health department should be contacted when an outbreak of Giardia is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/6\">",
"     6",
"    </a>",
"    ]. Involvement of the health department will facilitate identification and treatment of all symptomatic individuals, child care workers, and family members who are infected. Individuals with diarrhea should be excluded from child care centers until they are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/6\">",
"     6",
"    </a>",
"    ]. However, exclusion of asymptomatic carriers from child care is not necessary.",
"   </p>",
"   <p>",
"    Treatment of asymptomatic carriers is not effective for outbreak control, with the exception of asymptomatic carriers who are also food handlers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/6,47\">",
"     6,47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Waterborne infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Boiling or heating water to at least 70&ordm;C for 10 minutes eliminates Giardia cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/48\">",
"     48",
"    </a>",
"    ]. For hikers and campers, iodine-based water treatments are more effective than chlorine-based treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/48\">",
"     48",
"    </a>",
"    ]. High-quality water filtration units are also effective for Giardia cyst removal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/48\">",
"     48",
"    </a>",
"    ]. Information about water purification and a traveler's guide for buying water filters is available from the United States Centers for Disease Control and Prevention (",
"    <a class=\"external\" href=\"file://www.cdc.gov/travel/\">",
"     www.cdc.gov/travel/",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8967?source=see_link\">",
"     \"Travel advice\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with Giardia diarrhea should refrain from using recreational water venues (eg, swimming pools, lakes, rivers, etc.) until they have been asymptomatic for two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Breast-feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast milk contains detectable titers of secretory IgA, which is protective for nursing infants; this protective mechanism is particularly important in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/49\">",
"     49",
"    </a>",
"    ]. This was illustrated in a study from Egypt in which breast-fed infants had a lower incidence of symptomatic and asymptomatic infection with Giardia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6424/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, infected infants who were exclusively breast-fed had fewer clinical manifestations (anorexia, abdominal pain, and mucous in stool) than infants who were not exclusively breast-fed.",
"   </p>",
"   <p>",
"    Although breast-feeding may prevent Giardia in infants, if the mother is undergoing treatment for Giardia infection, the safety of continued breast-feeding depends upon the antibiotic therapy that is used to treat the mother.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/1/21522?source=see_link\">",
"       \"Patient information: Giardia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/0/28673?source=see_link\">",
"       \"Patient information: Giardia (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supportive measures for the treatment of children with symptomatic giardiasis include correction of fluid and electrolyte abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"       \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"       \"Treatment of hypovolemia (dehydration) in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link\">",
"       \"Oral rehydration therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend antimicrobial therapy for symptomatic patients with giardiasis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Treatment is not indicated for most patients with Giardia who are asymptomatic. To prevent the spread of infection, however, we suggest treatment of asymptomatic carriers who are food handlers, household contacts of pregnant women or immunocompromised individuals, or children in a day care or other setting who might transmit infection to others (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"       tinidazole",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"       nitazoxanide",
"      </a>",
"      as the drugs of choice for initial therapy (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Alternatives include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"       mebendazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"       paromomycin",
"      </a>",
"      , furazolidone, and quinacrine. Patients should be counseled to avoid lactose-containing foods for one month after therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no need to repeat the stool examination for parasite clearance in patients whose symptoms resolve. Patients with recurrent diarrhea should undergo reevaluation of the stool for parasites before empiric retreatment since the diarrhea may be related to lactose intolerance rather than recurrent Giardia. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Recurrence of symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal approach to relapse after treatment is uncertain. We suggest treatment with a drug from a different class (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternative approaches include treatment with a second course of the original agent, treatment with a longer course or higher dose of the original agent, or treatment with a combination of drugs. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Recurrence of symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Person-to-person spread of giardiasis can be prevented through strict handwashing, care with diaper disposal, and treatment of symptomatic patients. The local health department should be contacted when an outbreak of giardiasis is suspected. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Outbreaks'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Infection control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Waterborne Giardia infection can be prevented through effective treatment of drinking water. Individuals with giardiasis should refrain from using recreational water venues until they have been asymptomatic for two weeks. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Waterborne infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/1\">",
"      Kappus KD, Lundgren RG Jr, Juranek DD, et al. Intestinal parasitism in the United States: update on a continuing problem. Am J Trop Med Hyg 1994; 50:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/2\">",
"      Musher DM, Musher BL. Contagious acute gastrointestinal infections. N Engl J Med 2004; 351:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/3\">",
"      Yoder JS, Harral C, Beach MJ, Centers for Disease Control and Prevention (CDC). Giardiasis surveillance - United States, 2006-2008. MMWR Surveill Summ 2010; 59:15.",
"     </a>",
"    </li>",
"    <li>",
"     Hill DR, Nash TE. Intestinal flagellate and ciliate infections. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 2nd, Guerrant RL, Walker DA, Weller PF (Eds), WB Saunders, Philadelphia 1999. p.623.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/5\">",
"      Farthing MJ. Giardiasis. Gastroenterol Clin North Am 1996; 25:493.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Giardia intestinalis infections (Giardiasis). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/7\">",
"      Gilman RH, Marquis GS, Miranda E, et al. Rapid reinfection by Giardia lamblia after treatment in a hyperendemic Third World community. Lancet 1988; 1:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/8\">",
"      Gardner TB, Hill DR. Treatment of giardiasis. Clin Microbiol Rev 2001; 14:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/9\">",
"      Granados CE, Reveiz L, Uribe LG, Criollo CP. Drugs for treating giardiasis. Cochrane Database Syst Rev 2012; 12:CD007787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/10\">",
"      Ca&ntilde;ete R, Escobedo AA, Gonz&aacute;lez ME, et al. A randomized, controlled, open-label trial of a single day of mebendazole versus a single dose of tinidazole in the treatment of giardiasis in children. Curr Med Res Opin 2006; 22:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/11\">",
"      Tinidazole (Tindamax) - a new anti-protozoal drug. Med Lett Drugs Ther 2004; 46:70.",
"     </a>",
"    </li>",
"    <li>",
"     Presutti antiprotozoal agent Tindamax clears FDA; AWP is $18 per dose. In: \"The Pink Sheet\" vol 66, F-D-C Reports, Inc. Chevy Chase, MD 2004. p.10.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/13\">",
"      Chandy E, McCarthy J. Evidence behind the WHO guidelines: Hospital care for children: What is the most appropriate treatment for giardiasis? J Trop Pediatr 2009; 55:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/14\">",
"      Speelman P. Single-dose tinidazole for the treatment of giardiasis. Antimicrob Agents Chemother 1985; 27:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/15\">",
"      Escobedo AA, N&uacute;&ntilde;ez FA, Moreira I, et al. Comparison of chloroquine, albendazole and tinidazole in the treatment of children with giardiasis. Ann Trop Med Parasitol 2003; 97:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/16\">",
"      Pengsaa K, Limkittikul K, Pojjaroen-anant C, et al. Single-dose therapy for giardiasis in school-age children. Southeast Asian J Trop Med Public Health 2002; 33:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/17\">",
"      Fung HB, Doan TL. Tinidazole: a nitroimidazole antiprotozoal agent. Clin Ther 2005; 27:1859.",
"     </a>",
"    </li>",
"    <li>",
"     Tan, TQ. Giardiasis. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin, RD, Cherry, JD, Demmler-Harrison, GJ, Kaplan, SL (Eds), Saunders, Philadelphia, 2009. p. 2852.",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Drugs for parasitic infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012.",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections. Medical Lett Drugs Ther; August 2004 www.medletter.com/freedocs/parasitic.pdf (Accessed on March 08, 2005).",
"    </li>",
"    <li>",
"     Romark Alinia adult dose 'approvable'; anti-parasitic approved for children. In: \"The Pink Sheet,\" Vol 64, No 48, F-D-C Reports, Inc, Chevy Chase, MD 2002. p.11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/22\">",
"      Ortiz JJ, Ayoub A, Gargala G, et al. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther 2001; 15:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/23\">",
"      Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001; 184:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/24\">",
"      Davila-Gutierrez CE, Vasquez C, Trujillo-Hernandez B, Huerta M. Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. Am J Trop Med Hyg 2002; 66:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/25\">",
"      Diaz E, Mondragon J, Ramirez E, Bernal R. Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am J Trop Med Hyg 2003; 68:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/26\">",
"      Nitazoxanide (Alinia)--a new anti-protozoal agent. Med Lett Drugs Ther 2003; 45:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/27\">",
"      Cohen SA. Use of nitazoxanide as a new therapeutic option for persistent diarrhea: a pediatric perspective. Curr Med Res Opin 2005; 21:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/28\">",
"      Hall A, Nahar Q. Albendazole as a treatment for infections with Giardia duodenalis in children in Bangladesh. Trans R Soc Trop Med Hyg 1993; 87:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/29\">",
"      Misra PK, Kumar A, Agarwal V, Jagota SC. A comparative clinical trial of albendazole versus metronidazole in giardiasis. Indian Pediatr 1995; 32:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/30\">",
"      Dutta AK, Phadke MA, Bagade AC, et al. A randomised multicentre study to compare the safety and efficacy of albendazole and metronidazole in the treatment of giardiasis in children. Indian J Pediatr 1994; 61:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/31\">",
"      Canete R, Escobedo AA, Gonzalez ME, Almirall P. Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children. World J Gastroenterol 2006; 12:6366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/32\">",
"      Escobedo AA, Ca&ntilde;ete R, Gonzalez ME, et al. A randomized trial comparing mebendazole and secnidazole for the treatment of giardiasis. Ann Trop Med Parasitol 2003; 97:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/33\">",
"      Sadjjadi SM, Alborzi AW, Mostovfi H. Comparative clinical trial of mebendazole and metronidazole in giardiasis of children. J Trop Pediatr 2001; 47:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/34\">",
"      Craft JC, Murphy T, Nelson JD. Furazolidone and quinacrine. Comparative study of therapy for giardiasis in children. Am J Dis Child 1981; 135:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/35\">",
"      Hanevik K, Hausken T, Morken MH, et al. Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection. J Infect 2007; 55:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/36\">",
"      Hanevik K, M&oslash;rch K, Eide GE, et al. Effects of albendazole/metronidazole or tetracycline/folate treatments on persisting symptoms after Giardia infection: a randomized open clinical trial. Scand J Infect Dis 2008; 40:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/37\">",
"      Arg&uuml;ello-Garc&iacute;a R, Cruz-Soto M, Romero-Montoya L, Ortega-Pierres G. Variability and variation in drug susceptibility among Giardia duodenalis isolates and clones exposed to 5-nitroimidazoles and benzimidazoles in vitro. J Antimicrob Chemother 2004; 54:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/38\">",
"      Minenoa T, Avery MA. Giardiasis: recent progress in chemotherapy and drug development. Curr Pharm Des 2003; 9:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/39\">",
"      Dunn LA, Andrews KT, McCarthy JS, et al. The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis. Int J Antimicrob Agents 2007; 29:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/40\">",
"      Abboud P, Lem&eacute;e V, Gargala G, et al. Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2001; 32:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/41\">",
"      Gasc&oacute;n J, Ab&oacute;s R, Valls ME, Corach&aacute;n M. Mebendazole and metronidazole in giardial infections. Trans R Soc Trop Med Hyg 1990; 84:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/42\">",
"      Murphy TV, Nelson JD. Five v ten days' therapy with furazolidone for giardiasis. Am J Dis Child 1983; 137:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/43\">",
"      Goldin AJ, Hall A, Sarker RN, et al. Diagnosis of Giardia duodenalis infection in Bangladeshi infants: faecal antigen capture ELISA. Trans R Soc Trop Med Hyg 1993; 87:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/44\">",
"      Cacopardo B, Patamia I, Bonaccorso V, et al. [Synergic effect of albendazole plus metronidazole association in the treatment of metronidazole-resistant giardiasis]. Clin Ter 1995; 146:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/45\">",
"      M&oslash;rch K, Hanevik K, Robertson LJ, et al. Treatment-ladder and genetic characterisation of parasites in refractory giardiasis after an outbreak in Norway. J Infect 2008; 56:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/46\">",
"      Nash TE, Ohl CA, Thomas E, et al. Treatment of patients with refractory giardiasis. Clin Infect Dis 2001; 33:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/47\">",
"      Bartlett AV, Englender SJ, Jarvis BA, et al. Controlled trial of Giardia lamblia: control strategies in day care centers. Am J Public Health 1991; 81:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/48\">",
"      Ongerth JE, Johnson RL, Macdonald SC, et al. Back-country water treatment to prevent giardiasis. Am J Public Health 1989; 79:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/49\">",
"      Nayak N, Ganguly NK, Walia BN, et al. Specific secretory IgA in the milk of Giardia lamblia-infected and uninfected women. J Infect Dis 1987; 155:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6424/abstract/50\">",
"      Mahmud MA, Chappell CL, Hossain MM, et al. Impact of breast-feeding on Giardia lamblia infections in Bilbeis, Egypt. Am J Trop Med Hyg 2001; 65:257.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6024 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-EC95FD50DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6424=[""].join("\n");
var outline_f6_17_6424=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTIMICROBIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H838437\">",
"      - Nitroimidazoles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H838624\">",
"      Tinidazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Metronidazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Nitazoxanide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Albendazole or mebendazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Paromomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Furazolidone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Quinacrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RECURRENCE OF SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Infection control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Outbreaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Waterborne infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Breast-feeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/6024\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6024|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/16/35084\" title=\"table 1\">",
"      Treatment of giardiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=related_link\">",
"      Oral rehydration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/0/28673?source=related_link\">",
"      Patient information: Giardia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/1/21522?source=related_link\">",
"      Patient information: Giardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8967?source=related_link\">",
"      Travel advice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_17_6425="Phencyclidine (PCP) intoxication in adults";
var content_f6_17_6425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Phencyclidine (PCP) intoxication in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/17/6425/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/17/6425/contributors\">",
"     Kennon Heard, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/17/6425/contributors\">",
"     Jason Hoppe, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/17/6425/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/17/6425/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/17/6425/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/17/6425/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/17/6425/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite a fall in popularity since the 1970s, phencyclidine (PCP) remains a commonly abused drug that accounts for a significant number of poison center calls and hospitalizations. Early identification and prompt symptomatic treatment are vital to avoid possible sequelae, including rhabdomyolysis and seizures.",
"   </p>",
"   <p>",
"    Phencyclidine is a synthetic arylcycloalkylamine discovered in 1926, and subsequently developed as Sernyl in the 1950s for use as a nonnarcotic anesthetic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Sernyl exerted a calming effect at low anesthetic doses and induced cataplexy at higher doses, but it did not markedly suppress blood pressure or respiration. The use of Sernyl as a dissociative anesthetic was discontinued due to postoperative dysphoria and hallucinations, and by 1967 was limited to veterinary use [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/3\">",
"     3",
"    </a>",
"    ]. In April of 1979, all legal manufacturing of PCP in the United States was terminated [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the early 1970s a laboratory investigation of PCP derivatives led to the discovery of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    . Ketamine is 5 to 10 percent as potent as Sernyl and is now used clinically to induce dissociative anesthesia. Ketamine is also abused as a recreational drug.",
"   </p>",
"   <p>",
"    PCP's popularity as a drug of abuse peaked in the 1970s. During the late 1970s, one urban psychiatric hospital in the US found that 63 of 145 consecutive patients sampled over a 48-hour period tested positive for PCP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/5\">",
"     5",
"    </a>",
"    ]. Since that time, hospital visits and poison center calls related to PCP use have declined. Data from the American Association of Poison Control Centers reported 713 single exposures in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The basic pharmacology, clinical manifestations, and management of PCP intoxication in adults will be reviewed here. The management of PCP poisoning in children,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    poisoning, and other issues related to the management of the poisoned patient are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/570?source=see_link\">",
"     \"Phencyclidine (PCP) intoxication in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40935?source=see_link\">",
"     \"Ketamine poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCP, or 1-(1-phenylcyclohexyl) piperidine hydrochloride, is a dissociative anesthetic. It is synthesized from piperidine and cyclohexanone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/7\">",
"     7",
"    </a>",
"    ]. It is a weak base with a pKa of 8.6 and is soluble in water and ethanol&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCP is a stable white solid with a bitter taste. It is manufactured in many forms for recreational use, including powder, crystal, liquid, and tablets [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/3\">",
"     3",
"    </a>",
"    ]. It has been sprinkled on leaves for ingestion, and there are reports of it being combined with embalming fluid to enable the drug's uniform distribution in cigarettes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/9\">",
"     9",
"    </a>",
"    ]. Concentrations of the drug vary in PCP tablets (1 to 6 mg) and PCP-laced marijuana (1 to 10 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCP has a number of analogs that may also be abused, including PHP (rolicyclidine, phenylcyclohexylpyrrolidine), PCE (N-ethyl-1-phenylcyclohexylamine), TCP (1-[1-(2-thienyl) cyclohexyl] piperidine), and PCC (1-piperidinocyclohexane-carbonitrile). PCC is commonly found in street grade PCP. PCC has the potential for increased toxicity due to the release of hydrogen cyanide when smoked [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/7\">",
"     7",
"    </a>",
"    ], although acute cyanide toxicity is unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose of PCP varies depending upon the amount of active drug and the route. In general, symptoms first appear at 0.05",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    Alteration of body image has been reported at 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and 10 mg has been reported to cause catatonic stupor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCP is a noncompetitive antagonist of NMDA receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/14\">",
"     14",
"    </a>",
"    ]. It also stimulates sigma receptors and blocks the reuptake of biogenic amines. Stimulation of alpha adrenergic receptors is thought to be responsible for its sympathomimetic effects and cerebral vasospasm.",
"   </p>",
"   <p>",
"    PCP has three primary sites of action in the central nervous system:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      N-methyl-D-aspartate (NMDA) receptor complex &ndash; PCP has great affinity for NMDA receptor complexes in the hippocampus, neocortex, basal ganglia, and limbic system [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/14\">",
"       14",
"      </a>",
"      ]. NMDA antagonism at these sites produces acute psychosis that mimics schizophrenia in humans and leads to excess excitatory neurotransmitter release (eg, glutamate, glycine, aspartate) that can cause agitation and seizures.",
"     </li>",
"     <li>",
"      Dopamine, norepinephrine, and serotonin reuptake complex &ndash; PCP inhibits reuptake of dopamine, norepinephrine, and serotonin in neurons [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/15\">",
"       15",
"      </a>",
"      ]. This action contributes to the adrenergic and dopaminergic effects of PCP intoxication.",
"     </li>",
"     <li>",
"      Sigma receptor complex &ndash; PCP binding to the sigma receptor may explain, in part, the psychotic, anticholinergic, and movement abnormalities seen with intoxication [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absorption, peak serum concentration, and duration of effect vary with the route of PCP use. A retrospective study of 1000 patients found smoking to be the most common route (72 percent), usually via laced cigarettes or marijuana, followed by insufflation (13 percent), ingestion (12 percent), and intravenous (IV) injection (1.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/10\">",
"     10",
"    </a>",
"    ]. Smoking, insufflation, and IV or intramuscular routes produce symptoms within two to five minutes, while oral ingestion produces symptoms in 30 to 60 minutes.",
"   </p>",
"   <p>",
"    Smoking causes a rapid initial peak in plasma concentrations at five minutes and a second peak at 22 minutes. The second peak may be related to delayed absorption from the lungs. The mean half-life after smoking (24 + 7 hours) is similar to the IV route [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peak effect following ingestion is approximately 90 minutes. The duration of action (one to three hours) is similar to the IV route [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/17\">",
"     17",
"    </a>",
"    ]. PCP may undergo enterogastric recycling following oral doses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/18\">",
"     18",
"    </a>",
"    ]. Although not well absorbed in the stomach, PCP is actively secreted into the gastric fluid, where concentrations can reach 50 times that of the serum. It is then absorbed in the more alkaline small intestines.",
"   </p>",
"   <p>",
"    IV injection of PCP produces an immediate effect. Following IV injection, the duration of action is one to two hours, despite the long terminal half-life (21 + 3 hours).",
"   </p>",
"   <p>",
"    PCP has a large volume of distribution (6.2 + 0.3",
"    <span class=\"nowrap\">",
"     L/kg)",
"    </span>",
"    and is 65 percent protein bound [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/17\">",
"     17",
"    </a>",
"    ]. The drug's high lipid solubility accounts for the ease with which it crosses the blood brain barrier and enters adipose tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/14\">",
"     14",
"    </a>",
"    ]. Cerebrospinal fluid (CSF) levels are reported to be four times serum levels due to the slightly more acidic pH of the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCP displays first order kinetics with a half-life of 7 to 26 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elimination of PCP is principally by hepatic metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/17\">",
"     17",
"    </a>",
"    ]. It is rapidly metabolized in the liver to hydroxylated derivatives and excreted in the urine primarily as a mono-4-hydroxypiperidine conjugate. These metabolites are thought to have minimal pharmacologic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/8\">",
"     8",
"    </a>",
"    ]. Approximately 5 to 10 percent is excreted unchanged in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/18\">",
"     18",
"    </a>",
"    ]. A lower urine pH increases renal clearance, but this contributes little to overall elimination and may be dangerous. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Enhanced elimination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF OVERDOSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of phencyclidine (PCP) intoxication is made based upon the history and clinical evaluation. Unfortunately, a clear history is often unavailable as patients are frequently alone and exhibit alterations in mental status. Sometimes friends or emergency medical services personnel provide useful details. It can be helpful to know the street names for PCP, which include angel dust, embalming fluid, killer weed, peace pill, horse tranquilizer, and hog [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe poisoning can occur if a patient ingests large amounts of poorly packaged drug to avoid discovery by the authorities (body stuffing) or a break occurs in a container of concentrated drug that the patient has swallowed for the purpose of illicit transport (body packing). Coingestants are common with PCP use and may alter the clinical presentation or treatment. Marijuana cigarettes sometimes contain PCP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"     \"Internal concealment of drugs of abuse (body packing)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     General findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination should begin with an assessment of the patient's airway, breathing, circulation, and mental status. Although uncommon, patients with large PCP ingestions may present with profound CNS and respiratory depression requiring immediate endotracheal intubation. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    PCP intoxication can produce a wide range of vital signs and physical findings depending upon the amount ingested, the route of administration, patient susceptibility, and the presence of coingestants. Adrenergic stimulation is typical, but patients may exhibit central nervous system (CNS) stimulation or depression. Most patients are alert but experience hallucinations and demonstrate odd behavior and agitation similar to acute psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients may unexpectedly progress to coma, which may be prolonged. Because of this unpredictability, vital signs and clinical assessment should be repeated often until the patient has stabilized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Vital signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood pressure elevation is reported in 32 to 57 percent of patients with PCP intoxication. Systolic blood pressure correlates with elevated plasma drug concentrations and is significantly higher than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. According to a large retrospective case series, hypertension resolves in less than four hours in 62 percent of cases, but persists over 24 hours in 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/10\">",
"     10",
"    </a>",
"    ]. Spontaneous intracranial hemorrhage in association with uncontrolled hypertension has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tachycardia occurs in 30 to 43 percent of patients with a positive urine PCP test [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/10,23\">",
"     10,23",
"    </a>",
"    ]. In a case control study, tachycardia was more common in patients with confirmed PCP intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients may be hyperthermic (2.6 to 4 percent) or hypothermic (6.4 percent) depending upon the degree of psychomotor agitation and environmental conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/5,10\">",
"     5,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Neuropsychiatric findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;CNS signs and symptoms are common and vary widely. Patients may be alert with bizarre behavior, agitated or violent, or sedated and bordering on comatose. Furthermore, these symptoms may wax and wane over time. In one case series, 46 percent of patients were alert and oriented upon arrival to the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychomotor agitation occurs often, with observational data suggesting a rate between 34 and 64 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/10,23\">",
"     10,23",
"    </a>",
"    ]. Violence has been reported in 13 to 35 percent of patients and is more common in single drug exposures. According to a case series of 1000 confirmed PCP-intoxicated patients, 13 percent were involved in an altercation, of which 33 percent involved a gun or knife used to threaten others and 22 percent involved self-inflicted wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/10\">",
"     10",
"    </a>",
"    ]. Such violent behavior may be associated with delusions of super-human strength and diminished pain perception. Caregivers should be cautious when caring for agitated patients with possible PCP intoxication.",
"   </p>",
"   <p>",
"    In the same case series, psychomotor symptoms related to PCP intoxication were grouped into major and minor patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/10\">",
"     10",
"    </a>",
"    ]. Major symptoms, including acute brain syndrome, psychosis, catatonia, and coma, were associated with a more severe course and poorer outcomes. Complications included trauma (16 percent of patients), rhabdomyolysis (2.2 percent), and aspiration pneumonia (1 percent). Minor symptoms included lethargy or stupor and combinations of bizarre behavior, violence, agitation, and euphoria in patients who were otherwise alert and oriented. Minor symptoms were usually associated with a less severe clinical course.",
"   </p>",
"   <p>",
"    Acute brain syndrome, defined as disorientation combined with confusion, lack of judgment, inappropriate affect, or loss of memory, was the most common major symptom, reported in 37 percent of patients in one case series [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/28\">",
"     28",
"    </a>",
"    ]. Psychosis was reported in 16.6 percent of patients in the aforementioned series, including 63 percent of patients without coingestants. A smaller case series reported a high rate of auditory hallucinations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/5\">",
"     5",
"    </a>",
"    ]. Visual and tactile hallucinations can also occur. Full recovery from psychosis may take weeks to months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the case series cited above, catatonia was found in 11.7 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/28\">",
"     28",
"    </a>",
"    ]. In another series, approximately 6 percent of patients were reported to be wandering in public and 56 percent of them had disrobed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/10\">",
"     10",
"    </a>",
"    ]. Catatonia is typically of short duration with 85 percent of cases resolving by 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lethargy or stupor was reported in 3.8 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/28\">",
"     28",
"    </a>",
"    ]. Coma was reported in 11 percent of patients, with the duration of unconsciousness ranging from 30 minutes to seven days. A smaller case series reported that 50 percent of patients developed a decreased level of consciousness at some time during their clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Horizontal, vertical, or rotatory nystagmus is common with reported rates ranging from 57 to 89 percent of cases (",
"    <a class=\"graphic graphic_table graphicRef74834 \" href=\"UTD.htm?0/31/507\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. Other potential CNS effects include dystonic reactions, tardive dyskinesia, and athetosis, but these are rare. Symptoms such as ataxia, dysarthria, nausea, and vomiting may also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatalities in the setting of PCP intoxication are uncommon and most are secondary to trauma. Other causes include hyperthermia, respiratory arrest, and intracranial hemorrhage.",
"   </p>",
"   <p>",
"    Treating clinicians should be aware of the potential for multiple serious complications in patients with PCP intoxication. These occur most often with large ingestions and may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rhabdomyolysis",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Hypoglycemia",
"     </li>",
"     <li>",
"      Prolonged comatose state",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rhabdomyolysis developed in 2.2 percent of patients in one series of 1000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/28\">",
"     28",
"    </a>",
"    ] and hemodialysis was necessary in 0.3 percent. In another case series, 40 percent of patients with PCP-associated rhabdomyolysis (defined as myoglobinuria and a creatinine phosphokinase concentration above 16,000",
"    <span class=\"nowrap\">",
"     IU/L)",
"    </span>",
"    developed acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures occur infrequently, with estimates ranging from 2.6 to 6 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/5,10,30\">",
"     5,10,30",
"    </a>",
"    ]. Status epilepticus has been reported.",
"   </p>",
"   <p>",
"    Prolonged psychiatric illness may stem from an underlying condition or drug effect. Psychiatric evaluation should be obtained after a period of observation confirms the patient is medically stable. A retrospective review performed at a psychiatric facility found that 20 patients with new-onset PCP-induced psychosis needed shorter hospitalizations (average 4.8 days; range 1 to 9) compared with 20 patients with new-onset functional psychosis (13.9 days; range 3 to 41) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/31\">",
"     31",
"    </a>",
"    ]. However, there are reports of patients with PCP-induced psychosis requiring up to four to six weeks for full recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the variable presentation of PCP intoxication, the differential diagnosis is considerable. Other toxicologic causes that should be entertained in cases of altered mental status, hallucinations, and excessive adrenergic activity include sympathomimetics, anticholinergic toxicity, other hallucinogens (LSD, mescaline, and psilocybin), ethanol or sedative hypnotic drug withdrawal, neuroleptic malignant syndrome (NMS), serotonin syndrome, and salicylate toxicity (",
"    <a class=\"graphic graphic_table graphicRef59893 \" href=\"UTD.htm?3/43/3773\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70449 \" href=\"UTD.htm?1/11/1214\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34311?source=see_link\">",
"     \"Evaluation of abnormal behavior in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=see_link\">",
"     \"Methamphetamine intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=see_link\">",
"     \"Anticholinergic poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44584?source=see_link\">",
"     \"Intoxication from LSD and other common hallucinogens\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link\">",
"     \"Salicylate (aspirin) poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medical illness must also be considered. Altered mental status and vital sign abnormalities should lead to careful evaluation for central nervous system infections (encephalitis, meningitis) and sepsis. Metabolic etiologies such as hypoglycemia, hyponatremia, hyperthyroidism, and hypoxia are easily assessed and should be investigated. Occult head trauma can cause acute changes in mental status. Patients without apparent medical or toxicologic illness who remain symptomatic should be evaluated for possible psychosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     General testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory evaluation of the poisoned patient should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An electrocardiogram, to assess for cardiac conduction abnormalities",
"     </li>",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other laboratory studies are indicated in the setting of PCP intoxication, including creatine kinase, urine myoglobin, and liver transaminases. Further testing is performed based upon clinical assessment. As examples, BUN and creatinine are obtained if rhabdomyolysis or other potential causes of renal failure are suspected, while a CT of the head and evaluation of cerebrospinal fluid may be needed in the setting of a persistently altered mental status.",
"   </p>",
"   <p>",
"    The most common laboratory abnormalities associated with PCP intoxication include an elevated creatine kinase (70 percent), elevated liver transaminases (50 percent), hyperuricemia (24 percent), and hypoglycemia (22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Testing for PCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum and urine tests to determine PCP concentrations are available at some hospitals. However, the results of such tests are generally not available with sufficient speed to be of use during acute management.",
"   </p>",
"   <p>",
"    Serum concentrations were once widely available, but with the decreased prevalence of PCP, most labs offer qualitative testing only. Qualitative testing is more helpful than quantitative concentrations since serum levels do not correlate well with brain concentrations or clinical toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Confirmatory testing using gas chromatography with mass spectroscopy is performed on rare occasions when definitive drug identification is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US National Institute on Drug Abuse (NIDA) guidelines for federal workplace drug testing uses a cutoff urine PCP concentration of 25",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Urine toxicology screens may remain positive for several weeks. In one series of chronic users, urine screens remained positive for an average of 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/33\">",
"     33",
"    </a>",
"    ]. CSF testing has been reported in two cases with concentrations one to four times the serum levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple causes of false positive urine tests have been reported and the potential adverse medicolegal consequences of such results are profound. Drugs capable of causing a false positive urine test include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/34\">",
"     34",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/32,35\">",
"     32,35",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/36\">",
"     36",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/37\">",
"     37",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Airway, breathing, and circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial stabilization including a rapid assessment of the airway, breathing, and circulation is important. Airway protection with endotracheal intubation and mechanical ventilation was necessary in 1.2 percent of patients in one large case series [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/28\">",
"     28",
"    </a>",
"    ]. We suggest avoiding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    when performing rapid sequence intubation in patients with known or suspected PCP intoxication who exhibit significant psychomotor agitation or hyperthermia because of the risk of exacerbating rhabdomyolysis-related hyperkalemia.",
"   </p>",
"   <p>",
"    Some clinicians believe that PCP intoxication may increase airway secretions and the risk of laryngospasm, but such cases are likely to be extremely uncommon.",
"   </p>",
"   <p>",
"    Patients with concerning clinical findings (eg, stupor, hyperthermia) are placed on a cardiac monitor, given supplemental oxygen, and have intravenous access established. Abnormal vital signs are addressed immediately, and advanced life support measures are instituted as needed. Further acute interventions are based upon clinical findings, as quantitative testing for PCP is generally unavailable and unhelpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid control of psychomotor agitation is the cornerstone of successful management. Physical restraints may be necessary initially and several staff members are often needed to control patients agitated from PCP. Thereafter, chemical sedation is essential to control agitation, prevent or treat hyperthermia, perform a thorough physical examination, and obtain necessary studies.",
"   </p>",
"   <p>",
"    Little evidence exists to guide the use of sedatives in the management of PCP intoxication. Based upon observational reports and broad clinical experience, we believe benzodiazepines are the preferred agents to achieve chemical sedation.",
"   </p>",
"   <p>",
"    We treat severely agitated patients immediately with intravenous (IV) benzodiazepines (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    4 mg IV or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    5 to 10 mg IV). These doses can be repeated every eight to ten minutes based upon patient response.",
"   </p>",
"   <p>",
"    Butyrophenones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    2.5 mg or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    5 mg) may be used as adjunctive therapy when benzodiazepines do not adequately control symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/39\">",
"     39",
"    </a>",
"    ]. These doses may be repeated. Some clinicians prefer to avoid butyrophenones because they are purported to lower the seizure threshold and impair heat dissipation in hyperthermic patients. However, there are no high quality studies in humans to support such claims.",
"   </p>",
"   <p>",
"    Although IV administration of sedatives and antipsychotics is strongly preferred in severely intoxicated patients, intramuscular (IM) injection may be used if IV access is unavailable. IM injection may provide sufficient sedation to allow definitive care, including placement of IV catheters.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     Midazolam",
"    </a>",
"    (5 mg IM) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    (10 mg IM) may be used in such situations.",
"   </p>",
"   <p>",
"    In the rare case of severe refractory psychomotor agitation or status epilepticus, treatment with a barbiturate or a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    infusion may be necessary. Endotracheal intubation and mechanical ventilation are commonly required in such instances.",
"   </p>",
"   <p>",
"    We treat mildly or moderately intoxicated patients with benzodiazepines and a quiet environment.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    1 to 2 mg IV or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    2 to 5 mg IV may be adequate, and should be repeated as needed. Small observational studies suggest that sensory deprivation (dark, quiet room; hands covered) may decrease agitation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment of complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once adequate sedation is achieved, the patient with PCP intoxication should be carefully examined for secondary injuries. PCP intoxication often leads to bizarre behavior, hallucinations, delusions of physical prowess, and a diminished perception of pain. As a result, PCP abuse is often associated with trauma. A large case series reported injuries in 13 percent of patients, 22 percent of which were self-inflicted [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other major potential complications of PCP intoxication include hyperthermia, seizures, rhabdomyolysis, and hypertension. Hyperthermia typically improves with adequate sedation, but external cooling and, in a small number of severe refractory cases, even paralysis and mechanical ventilation may be necessary. Hypertension is typically transient and rarely requires pharmacologic intervention beyond sedation. Refractory hypertension can be treated with short acting agents such as nitroglycerine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    that can be titrated to effect. Cardiac monitoring and frequent reexamination are essential in patients with any significant complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=see_link\">",
"     \"Status epilepticus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=see_link\">",
"     \"Treatment of specific hypertensive emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Animal studies suggest that antipsychotic medications can block PCP mediated behavioral effects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/41\">",
"     41",
"    </a>",
"    ]. Clinical trials in humans are needed before this approach can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients survive PCP intoxication uneventfully with supportive care; decontamination is generally unnecessary in isolated ingestions. However, decontamination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) may be useful if a massive ingestion or a potentially dangerous coingestant is present and treatment is started within one hour of ingestion. Patients who ingest large amounts of PCP to avoid police detection (body stuffers) or to transport drug for distribution (body packers) may sustain massive ingestions. Any potential benefit from AC must be weighed against the risk of aspiration, especially given the potential for altered mental status and seizures with severe PCP intoxication. AC is given in a dose of 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    (maximum 50 g).",
"   </p>",
"   <p>",
"    We do NOT typically use multi-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (MDAC) in patients with PCP intoxication. MDAC provides a theoretical benefit because of the extensive enterohepatic recirculation of PCP. Dogs treated with AC following oral doses of PCP demonstrated decreased duration of anesthesia, seizures, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/42\">",
"     42",
"    </a>",
"    ]. Giving rats activated charcoal following an oral dose of PCP significantly elevated the lethal dose (LD50) of PCP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/42\">",
"     42",
"    </a>",
"    ]. However, there is no evidence of clinical benefit in humans, and the potential for aspiration exists whenever AC is given.",
"   </p>",
"   <p>",
"    We do NOT suggest the use of nasogastric suction in patients with PCP intoxication. Nasogastric suction is theoretically beneficial when performed soon after ingestion due to the high concentration of PCP in the stomach's acidic environment. However, it has no proven benefit and may cause electrolyte abnormalities, aspiration, and unwanted difficulty in agitated patients.",
"   </p>",
"   <p>",
"    Whole bowel irrigation is NOT routinely recommended. It should only be used in patients who have ingested potentially lethal amounts of PCP, as may occur with body stuffers or body packers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"     \"Internal concealment of drugs of abuse (body packing)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Enhanced elimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither urine acidification nor charcoal hemoperfusion should be used in the treatment of PCP intoxication.",
"   </p>",
"   <p>",
"    Although some toxicologists have proposed urinary acidification as a means of increasing PCP clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/18\">",
"     18",
"    </a>",
"    ], this process increases total drug clearance by only one percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. Moreover, acidification increases the potential for systemic acidosis, worsening rhabdomyolysis and renal damage, and precipitation of uric acid leading to nephrolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of dogs loaded with 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of PCP, charcoal hemoperfusion failed to reduce the number of seizures, duration of coma, or tissue concentration compared with control animals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/44\">",
"     44",
"    </a>",
"    ]. Only 2 percent of the parent compound was recovered. The authors concluded that PCP's high volume of distribution, high lipid solubility, and low plasma concentration make removal by hemoperfusion ineffective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the variable course of PCP toxicity, even patients without severe symptoms or complications benefit from some period of observation. Patients presenting early following an ingestion may be asymptomatic initially but should be observed for at least six hours. Patients with mild symptoms presenting a few hours after the onset of intoxication generally recover within several hours. Such patients may be discharged provided the effects of intoxication have resolved and the patient remains symptom-free during a brief (one to two hours) period of observation.",
"   </p>",
"   <p>",
"    Any patient with significant complications (eg, rhabdomyolysis, coma, status epilepticus) or severe symptoms (eg, uncontrolled hypertension, hyperthermia) should be admitted to an intensive care setting. Patients with less severe but persistent symptoms should be admitted to an appropriate ward for further monitoring and treatment.",
"   </p>",
"   <p>",
"    Psychiatric evaluation should be obtained where appropriate, once medical problems have been addressed. Chronic abusers may benefit from treatment for substance abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     FUTURE CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care remains the cornerstone of the management of PCP toxicity. However, the use of monoclonal antibodies to reverse toxicity is being studied and may provide an alternative approach in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Monoclonal anti-phencyclidine Fab antibody fragments successfully reversed PCP-induced locomotor effects in a rat model [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6425/abstract/45\">",
"     45",
"    </a>",
"    ]. These antibodies are not able to cross the blood brain barrier and directly reverse receptor binding. However, the antibodies decrease the concentration of free PCP and alter its pharmacokinetics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of PCP intoxication is different in infants and young children than in adolescents or adults. The diagnosis and management of children with PCP intoxication is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/570?source=see_link\">",
"     \"Phencyclidine (PCP) intoxication in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89018971\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phencyclidine (ie, PCP) is a dissociative anesthetic that is abused primarily for its hallucinatory effects. Significant toxicity is rare but potentially serious. The drug's onset of action is rapid, but the duration of action is generally brief (one to four hours). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology and cellular toxicology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Kinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of PCP intoxication vary depending upon the route of exposure, dose, and coingestants, and may include altered mental status (from comatose to profound psychomotor agitation), hallucinations, hypertension, tachycardia, and multidirectional nystagmus. Severe complications may include traumatic injuries, rhabdomyolysis, hyperthermia, and seizures. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features of overdose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Due to the variable presentation of PCP intoxication, the differential diagnosis is considerable. It is reviewed in the text. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Quantitative drug concentrations have little role in the management of acute toxicity. Qualitative testing is available, but false positives are frequent. Results may remain positive for weeks. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Testing for PCP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid control of psychomotor agitation is the cornerstone of successful management. Physical restraints may be necessary initially and several staff members are often needed to control patients agitated from PCP. Chemical sedation should be administered as rapidly as possible. Decontamination and other aspects of management are discussed above. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with PCP-related psychomotor agitation who require sedation, we suggest the use of benzodiazepines (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We treat severely agitated patients immediately with intravenous (IV) benzodiazepines (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      4 mg IV or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      5 to 10 mg IV). These doses can be repeated every eight to ten minutes based upon patient response. In severely intoxicated patients, intramuscular (IM) injection may be used initially if IV access is unavailable.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       Midazolam",
"      </a>",
"      (5 mg IM) may be used in such situations. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Sedation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We treat mildly or moderately intoxicated patients with benzodiazepines and a quiet environment.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       Lorazepam",
"      </a>",
"      1 to 2 mg IV or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      2 to 5 mg IV may be adequate, and may be repeated as needed. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Sedation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with significant symptoms should be admitted to a monitored setting. Due to the relatively short duration of action, patients with mild symptoms are candidates for a period of observation and discharge. Patients whose medical symptoms resolve but have persistent behavioral issues should undergo a psychiatric evaluation. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Pali, MJ, Tharratt, RS, Albertson, TE. Phencyclidine and its congeners. In: Critical Care Toxicology, 1st, Brent, J, Wallace, KL, Burkhart, KK, et al (Eds), Mosby, Philadelphia 2005. p.777.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/2\">",
"      CHEN G, ENSOR CR, RUSSELL D, BOHNER B. The pharmacology of 1-(1-phenylcyclohexyl) piperidine-HCl. J Pharmacol Exp Ther 1959; 127:241.",
"     </a>",
"    </li>",
"    <li>",
"     Olmedo, R. Phencyclidine and ketamine. In: Goldfrank's Toxicologic Emergencies, 8th, Flomenbaum, NE, Goldfrank, LR, Hoffman, RS, et al (Eds), McGraw-Hill, New York 2006. p.1231.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/4\">",
"      Wright HH, Cole EA, Batey SR, Hanna K. Phencyclidine-induced psychosis: eight-year follow-up of ten cases. South Med J 1988; 81:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/5\">",
"      Yago KB, Pitts FN Jr, Burgoyne RW, et al. The urban epidemic of phencyclidine (PCP) use: clinical and laboratory evidence from a public psychiatric hospital emergency service. J Clin Psychiatry 1981; 42:193.",
"     </a>",
"    </li>",
"    <li>",
"     American Association of Poison Control Centers. file://www.aapcc.org/ (Accessed on November 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/7\">",
"      Shesser R, Jotte R, Olshaker J. The contribution of impurities to the acute morbidity of illegal drug use. Am J Emerg Med 1991; 9:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/8\">",
"      Liden CB, Lovejoy FH Jr, Costello CE. Phencyclidine. Nine cases of poisoning. JAMA 1975; 234:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/9\">",
"      Holland JA, Nelson L, Ravikumar PR, Elwood WN. Embalming fluid-soaked marijuana: new high or new guise for PCP? J Psychoactive Drugs 1998; 30:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/10\">",
"      McCarron MM, Schulze BW, Thompson GA, et al. Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. Ann Emerg Med 1981; 10:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/11\">",
"      Cook CE, Brine DR, Jeffcoat AR, et al. Phencyclidine disposition after intravenous and oral doses. Clin Pharmacol Ther 1982; 31:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/12\">",
"      Tschirgi T. Phencyclidine: A hidden risk of illicit drug use. Pharm Alert 1990; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/13\">",
"      Aniline O, Pitts FN Jr. Phencyclidine (PCP): a review and perspectives. Crit Rev Toxicol 1982; 10:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/14\">",
"      Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/15\">",
"      Akunne HC, Reid AA, Thurkauf A, et al. [3H]1-[2-(2-thienyl)cyclohexyl]piperidine labels two high-affinity binding sites in human cortex: further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex. Synapse 1991; 8:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/16\">",
"      Wolfe SA Jr, De Souza EB. Sigma and phencyclidine receptors in the brain-endocrine-immune axis. NIDA Res Monogr 1993; 133:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/17\">",
"      Cook CE, Brine DR, Quin GD, et al. Phencyclidine and phenylcyclohexene disposition after smoking phencyclidine. Clin Pharmacol Ther 1982; 31:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/18\">",
"      Aronow R, Done AK. Phencyclidine overdose: an emerging concept of management. JACEP 1978; 7:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/19\">",
"      Donaldson JO, Baselt RC. CSF phencyclidine. Am J Psychiatry 1979; 136:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/20\">",
"      Jackson JE. Phencyclidine pharmacokinetics after a massive overdose. Ann Intern Med 1989; 111:613.",
"     </a>",
"    </li>",
"    <li>",
"     Caravatti, EM. Hallucinogenic drugs. In: Medical Toxicology, 3rd, Dart, RC, Caravatti, EM, McGuigan, MA, et al (Eds), Lippincott, Williams, and Wilkins, Philadelphia 2004. p.1106.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/22\">",
"      Milhorn HT Jr. Diagnosis and management of phencyclidine intoxication. Am Fam Physician 1991; 43:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/23\">",
"      Bailey DN. Phencyclidine abuse. Clinical findings and concentrations in biological fluids after nonfatal intoxication. Am J Clin Pathol 1979; 72:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/24\">",
"      Barton CH, Sterling ML, Vaziri ND. Phencyclidine intoxication: clinical experience in 27 cases confirmed by urine assay. Ann Emerg Med 1981; 10:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/25\">",
"      Bessen HA. Intracranial hemorrhage associated with phencyclidine abuse. JAMA 1982; 248:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/26\">",
"      Eastman JW, Cohen SN. Hypertensive crisis and death associated with phencyclidine poisoning. JAMA 1975; 231:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/27\">",
"      Crosley CJ, Binet EF. Cerebrovascular complications in phencyclidine intoxication. J Pediatr 1979; 94:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/28\">",
"      McCarron MM, Schulze BW, Thompson GA, et al. Acute phencyclidine intoxication: clinical patterns, complications, and treatment. Ann Emerg Med 1981; 10:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/29\">",
"      Akmal M, Valdin JR, McCarron MM, Massry SG. Rhabdomyolysis with and without acute renal failure in patients with phencyclidine intoxication. Am J Nephrol 1981; 1:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/30\">",
"      Kessler GF Jr, Demers LM, Berlin C, Brennan RW. Letter: Phencyclidine and fatal status epilepticus. N Engl J Med 1974; 291:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/31\">",
"      Carls KA, Ruehter VL. An evaluation of phencyclidine (PCP) psychosis: a retrospective analysis at a state facility. Am J Drug Alcohol Abuse 2006; 32:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/32\">",
"      Budai B, Iskandar H. Dextromethorphan can produce false positive phencyclidine testing with HPLC. Am J Emerg Med 2002; 20:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/33\">",
"      Simpson GM, Khajawall AM, Alatorre E, Staples FR. Urinary phencyclidine excretion in chronic abusers. J Toxicol Clin Toxicol 1982; 19:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/34\">",
"      Hoffman, RJ, Saddock, V, Nelson, L. Effect of ketamine on phencyclidine immunoassays (abstract). J Toxicol Clin Toxicol 2001; 39:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/35\">",
"      Schier J. Avoid unfavorable consequences: dextromethorpan can bring about a false-positive phencyclidine urine drug screen. J Emerg Med 2000; 18:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/36\">",
"      Levine BS, Smith ML. Effects of diphenhydramine on immunoassays of phencyclidine in urine. Clin Chem 1990; 36:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/37\">",
"      Santos PM, L&oacute;pez-Garc&iacute;a P, Navarro JS, et al. False positive phencyclidine results caused by venlafaxine. Am J Psychiatry 2007; 164:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/38\">",
"      Hull MJ, Griggs D, Knoepp SM, et al. Postmortem urine immunoassay showing false-positive phencyclidine reactivity in a case of fatal tramadol overdose. Am J Forensic Med Pathol 2006; 27:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/39\">",
"      Giannini, AJ, Nageotte, C, Loiselle, RH, et al. Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity. J Toxicol Clin Toxicol 1984-1985; 22:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/40\">",
"      COHEN BD, LUBY ED, ROSENBAUM G, GOTTLIEB JS. Combined sernyl and sensory deprivation. Compr Psychiatry 1960; 1:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/41\">",
"      Grayson B, Idris NF, Neill JC. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 2007; 184:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/42\">",
"      Picchioni AL, Consroe PF. Activated charcoal--a phencyclidine antidote, or hog in dogs. N Engl J Med 1979; 300:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/43\">",
"      Barton CH, Sterling ML, Vaziri ND. Rhabdomyolysis and acute renal failure associated with phencyclidine intoxication. Arch Intern Med 1980; 140:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/44\">",
"      Allen WR, O'Barr TP, Corby DG. Hemoperfusion of phencyclidine in the dog. Int J Artif Organs 1985; 8:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/45\">",
"      Hardin JS, Wessinger WD, Proksch JW, Owens SM. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs. J Pharmacol Exp Ther 1998; 285:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6425/abstract/46\">",
"      Lacy HM, Gunnell MG, Laurenzana EM, Owens SM. Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody. Int Immunopharmacol 2008; 8:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 313 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6425=[""].join("\n");
var outline_f6_17_6425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES OF OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - General findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Vital signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Neuropsychiatric findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      General testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Testing for PCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Airway, breathing, and circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Enhanced elimination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      FUTURE CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89018971\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/313\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/313|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/31/507\" title=\"table 1\">",
"      Poisons causing nystagmus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/43/3773\" title=\"table 2\">",
"      Causes of delirium and confusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/11/1214\" title=\"table 3\">",
"      Drugs that cause or prolong delirium",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34311?source=related_link\">",
"      Evaluation of abnormal behavior in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=related_link\">",
"      Internal concealment of drugs of abuse (body packing)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44584?source=related_link\">",
"      Intoxication from LSD and other common hallucinogens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40935?source=related_link\">",
"      Ketamine poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=related_link\">",
"      Methamphetamine intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/570?source=related_link\">",
"      Phencyclidine (PCP) intoxication in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=related_link\">",
"      Salicylate (aspirin) poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=related_link\">",
"      Treatment of specific hypertensive emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_17_6426="Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)";
var content_f6_17_6426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/17/6426/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/17/6426/contributors\">",
"     Elizabeth A Stewart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/17/6426/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/17/6426/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/17/6426/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/17/6426/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/17/6426/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine leiomyomas (fibroids or myomas) are the most common pelvic tumor in women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. They are benign monoclonal tumors arising from the smooth muscle cells of the myometrium. They arise in reproductive age women and typically present with symptoms of abnormal uterine bleeding or pelvic",
"    <span class=\"nowrap\">",
"     pain/pressure.",
"    </span>",
"    Uterine fibroids may also have reproductive effects (eg, infertility, adverse pregnancy outcomes).",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas are reviewed here. Treatment of uterine leiomyomas, leiomyoma histology and pathogenesis, differentiating leiomyomas from uterine sarcomas, and leiomyoma variants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25143?source=see_link\">",
"     \"Histology and pathogenesis of uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=see_link\">",
"     \"Differentiating uterine leiomyomas (fibroids) from uterine sarcomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17465?source=see_link\">",
"     \"Variants of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY AND LOCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibroids are often described according to their location in the uterus, although many fibroids have more than one location designation (",
"    <a class=\"graphic graphic_figure graphicRef53241 \" href=\"UTD.htm?30/16/30978\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80897 graphicRef59079 \" href=\"UTD.htm?42/46/43752\">",
"     picture 1A-B",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intramural myomas &ndash; These leiomyomas develop from within the uterine wall. They may enlarge sufficiently to distort the uterine cavity or serosal surface. Some fibroids can be transmural and extend from the serosal to the mucosal surface.",
"     </li>",
"     <li>",
"      Submucosal myomas &ndash; These leiomyomas derive from myometrial cells just below the endometrium. These neoplasms often protrude into the uterine cavity. The extent of this protrusion is described by the European Society of Hysteroscopy classification system and is clinically relevant for predicting outcomes of hysteroscopic myomectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/4\">",
"       4",
"      </a>",
"      ]. A type 0 fibroid is completely intracavitary, type I has less than 50 percent of its volume in the uterine wall, whereas a type II has 50 percent or more of its volume in the uterine wall (",
"      <a class=\"graphic graphic_figure graphicRef59668 \" href=\"UTD.htm?26/32/27143\">",
"       figure 2",
"      </a>",
"      ). Types 0 and I are hysteroscopically resectable, although significant hysteroscopic expertise may be needed to resect type I masses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32601?source=see_link&amp;anchor=H6#H6\">",
"       \"Hysteroscopic myomectomy\", section on 'Myometrial penetration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subserosal myomas &ndash; These leiomyomas originate from the myometrium at the serosal surface of the uterus. They can have a broad or pedunculated base (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63661 \" href=\"UTD.htm?8/34/8737\">",
"       image 1",
"      </a>",
"      ) and may be intraligamentary (ie, extending between the folds of the broad ligament).",
"     </li>",
"     <li>",
"      Cervical myomas &ndash; These leiomyomas are located in the cervix, rather than the uterine corpus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine leiomyomas are the most common pelvic tumor in women, as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. A hysterectomy study found myomas in 77 percent of uterine specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology of leiomyomas parallels the ontogeny and life cycle changes of the reproductive hormones estrogen and progesterone. Although the growth of fibroids is responsive to gonadal steroids, these hormones are not necessarily responsible for the genesis of the tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25143?source=see_link&amp;anchor=H7#H7\">",
"     \"Histology and pathogenesis of uterine leiomyomas (fibroids)\", section on 'Steroid hormones'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Leiomyomas have not been described in prepubertal girls, but they are occasionally noted in adolescents. Myomas are clinically apparent in approximately 12 to 25 percent of reproductive age women and noted on pathological examination in approximately 80 percent of surgically excised uteri [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]. In hysterectomy specimens sectioned at 2-mm intervals, premenopausal women had an average 7.6 fibroids [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/5\">",
"     5",
"    </a>",
"    ]. Most, but not all, women have shrinkage of leiomyomas at menopause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30312561\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30312569\">",
"    <span class=\"h2\">",
"     Race",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence rates of fibroids are typically found to be two- to three-fold greater in black women than in white women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]. In one study, the estimated cumulative incidence of fibroids of any size, including very small tumors, by age 50 was &gt;80 percent for black women and almost 70 percent for white women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/1\">",
"     1",
"    </a>",
"    ]. Clinically relevant fibroids (uterine enlargement greater than or equal to nine weeks size, fibroid greater than or equal to 4 cm, or submucosal fibroid) are detectable by transvaginal sonography in approximately 50 percent of black women in the menopausal transition and 35 percent of white women in the menopausal transition [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of the increased incidence of leiomyomas in black women is unknown. It cannot be explained by known factors that vary by race [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/8\">",
"     8",
"    </a>",
"    ]. There have been studies that correlated the presence of fibroids in African American women with polycystic ovarian syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/9\">",
"     9",
"    </a>",
"    ] and self-reported experience of racism [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of leiomyomas also differs by race. Most white women with symptomatic fibroids are in their 30s or 40s; however, black women develop symptoms on average four to six years younger and may even present with disease in their 20s [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In addition, it appears that fibroids grow at a slower rate after age 35 in white women, but not in black women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/13\">",
"     13",
"    </a>",
"    ]. Compared with white women, black women experience more severe disease based on their symptoms in a proposed severity algorithm and have more extensive disease at the time of hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of hysterectomy for fibroids is greater among black women than among white women (38 versus 16 per 10,000 women) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/14\">",
"     14",
"    </a>",
"    ]. Also, among women undergoing hysterectomy, black women appear to have surgery at a younger age, have larger uteri, and more severe anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are mixed regarding whether Latina women have an increased risk of uterine myomas compared with non-Latina white women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. The risk was 1.3-fold in a prospective study of 133,000 women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/14\">",
"     14",
"    </a>",
"    ]. Some of this variation may be accounted for whether black Latina women are included in the analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30312671\">",
"    <span class=\"h2\">",
"     Menstrual history and parity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early menarche (&lt;10 years old) is associated with an increased risk of developing fibroids. This may largely account for the early onset of disease in black women in whom menarche is generally earlier than in white women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/11,15-18\">",
"     11,15-18",
"    </a>",
"    ]. Additionally, prenatal exposure to diethylstilbestrol is associated with an increased risk of fibroids, supporting the role of early hormonal exposure in pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/19\">",
"     19",
"    </a>",
"    ]. In white women, a specific polymorphism in the transcription factor HMGA2 appears to be linked to both uterine leiomyomas and shorter adult height, suggesting that early menarche may be a key influence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parity (having one or more pregnancies extending beyond 20 weeks) decreases the chance of fibroid formation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. It has been hypothesized that the postpartum remodeling of the uterus may have the effect of clearing smaller fibroids [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/23\">",
"     23",
"    </a>",
"    ]. Recent studies supported this hypothesis with the finding that over a third of women with a single fibroid identified during pregnancy had none on postpartum ultrasound, and almost 80 percent of fibroids were smaller following pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/24\">",
"     24",
"    </a>",
"    ]. In some cohorts, early age at first birth decreases risk and a longer interval since last birth increases risk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5291214\">",
"    <span class=\"h2\">",
"     Hormonal contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of low dose oral contraceptives (OCs) does not cause fibroids to grow, therefore administration of these drugs is not contraindicated in women with fibroids [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/15,20,25-27\">",
"     15,20,25-27",
"    </a>",
"    ]. One possible exception was reported by the Nurses' Health Study, which suggested OC use increased the risk of leiomyomas in women with early exposure to OCs (13 and 16 years old) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long acting progestin-only contraceptives (eg, depot medroxyprogesterone) protect against development of leiomyomas [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/15,27,28\">",
"     15,27,28",
"    </a>",
"    ]. However, recent studies of postpartum fibroid regression suggest that these agents inhibit fibroid regression when used in the postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2751993\">",
"    <span class=\"h2\">",
"     Ovulation induction agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are isolated reports of leiomyoma enlargement in women treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. However, both cases reported occurred in the era before clinical use of ultrasound and the only presurgical assessment of the size of fibroids was pelvic examination and culdoscopy. Given the frequency of ultrasound monitoring in conjunction with current fertility treatments and the dearth of case reports, the association of fibroid growth with agents for ovulation induction is unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5286725\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies show a relationship between fibroids and increasing body mass index; however, a relationship with increased body mass index, weight gain as an adult, or body fat varies between studies. The relationship is complex and is likely modified by other factors, such as parity, and may be more related to change in body habitus as an adult [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/25,33-37\">",
"     25,33-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30313102\">",
"    <span class=\"h2\">",
"     Diet, caffeine, and alcohol use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant consumption of beef and other reds meats (1.7-fold) or ham (1.3-fold) is associated with an increased relative risk of fibroids and consumption of green vegetables (0.5-fold) and fruit (especially citrus fruit) with a decreased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. One report suggested that consumption of dairy products, but not soy products, is inversely related to fibroid risk in black women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/40\">",
"     40",
"    </a>",
"    ]. Dietary consumption of carotenoids is not associated with a change in risk for uterine leiomyoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/41\">",
"     41",
"    </a>",
"    ]. Recent data suggest that consumption of dairy products is inversely associated with leiomyoma risk in black women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/40\">",
"     40",
"    </a>",
"    ]. There was no confounding effect of soy consumption, which is often a substitute for dairy products in lactose intolerant women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/40\">",
"     40",
"    </a>",
"    ]. Dietary vitamin A from animal sources may also be associated with decreased fibroid risk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/39\">",
"     39",
"    </a>",
"    ]. Increases in dietary glycemic index or load are associated with a weak increase in fibroid risk in some women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consumption of alcohol, especially beer, appears to increase the risk of developing fibroids [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caffeine consumption is not a risk factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5286804\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking decreases the risk of having fibroids through an unknown mechanism. Smoking does not appear to affect estrogen metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/20,44\">",
"     20,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5286904\">",
"    <span class=\"h2\">",
"     Heredity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies imply a familial predisposition to leiomyomas in some women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25143?source=see_link&amp;anchor=H3#H3\">",
"     \"Histology and pathogenesis of uterine leiomyomas (fibroids)\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5286678\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is associated with an increased leiomyoma risk. The risk is related to increased duration or severity of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/45\">",
"     45",
"    </a>",
"    ]. Environmental phthalate exposure appears to be linked to an increased risk of fibroids, especially in women with concomitant endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several measures of uterine infection appear to be associated with an increased risk of leiomyomas. This is consistent with the hypothesis that uterine injury may lead to leiomyoma formation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/45,47\">",
"     45,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms attributable to uterine myomas can generally be classified into three distinct categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal uterine bleeding",
"     </li>",
"     <li>",
"      Pelvic pressure and pain",
"     </li>",
"     <li>",
"      Reproductive dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the majority of myomas are small and asymptomatic, many women with fibroids have significant problems that interfere with some aspect of their lives and warrant therapy. These symptoms are related to the number, size, and location of the neoplasms. Myomas can occur as single or multiple tumors and range in size from microscopic to tens of centimeters. The size of the myomatous uterus is described in menstrual weeks, as with the gravid uterus. As an example, a 20-week size myomatous uterus is not unusual, and is often associated with heavy menses, increasing abdominal girth, and a sense of abdominal fullness similar to pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Abnormal uterine bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal uterine bleeding is the most common symptom. Heavy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolonged menses is the typical bleeding pattern with myomas [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/48\">",
"     48",
"    </a>",
"    ]. Intermenstrual bleeding and postmenopausal bleeding are",
"    <strong>",
"     NOT",
"    </strong>",
"    characteristic of myomas and should be investigated to exclude endometrial pathology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    .) Heavy uterine bleeding may be responsible for associated problems, such as iron deficiency anemia, social embarrassment, and lost productivity in the work force.",
"   </p>",
"   <p>",
"    The presence and degree of uterine bleeding are determined, in large part, by the location of the fibroid; size is of secondary importance. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Terminology and location'",
"    </a>",
"    above.) Submucosal myomas that protrude into the uterine cavity (eg, types 0 and I) (",
"    <a class=\"graphic graphic_figure graphicRef59668 \" href=\"UTD.htm?26/32/27143\">",
"     figure 2",
"    </a>",
"    ) are most frequently related to significant menorrhagia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/2,4,49\">",
"     2,4,49",
"    </a>",
"    ]. However, women with intramural myomas also commonly experience heavy or prolonged menstrual bleeding. The mechanism(s) of profuse menses are unclear, but may include both microscopic and macroscopic abnormalities of the uterine vasculature, impaired endometrial hemostasis, or molecular dysregulation of angiogenic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pelvic pressure and pain",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5287048\">",
"    <span class=\"h3\">",
"     Bulk-related symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myomatous uterus is irregularly shaped, in contrast to the pregnant uterus, and can cause specific symptoms due to pressure from myomas at particular locations. As examples, urinary frequency, difficulty emptying the bladder, and, rarely, urinary obstruction can all occur with fibroids; symptoms sometimes arise when an anterior fibroid presses directly on the bladder or a posterior fibroid pushes the entire uterus forward. Silent, ureteric compression leading to renal hydronephrosis is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/51\">",
"     51",
"    </a>",
"    ]. Fibroids that place pressure on the rectum can result in constipation. Back pain may, on occasion, be related to the presence of myomas, but other possible causes should be considered. Very large uteri may compress the vena cava and lead to increase in thromboembolic risk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. At least one study suggests the risk of venous thromboembolism is likely to be the presenting complaint associated with an enlarged uterus rather than a postsurgical complication [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5287480\">",
"    <span class=\"h3\">",
"     Dysmenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysmenorrhea is also reported by many women with fibroids. This pain in many women appears to be correlated with heavy menstrual flow",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    passage of clots.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5287055\">",
"    <span class=\"h3\">",
"     Dyspareunia",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is controversial whether women with fibroids in any location are more likely to experience dyspareunia than women without fibroids [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. However, among women with fibroids, anterior or fundal fibroids are the most likely to be associated with deep dyspareunia. Number and size of fibroids do not appear to influence the incidence or intensity of dyspareunia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5287062\">",
"    <span class=\"h3\">",
"     Leiomyoma degeneration or torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequently, fibroids cause acute pain from degeneration (eg, carneous or red degeneration) or torsion of a pedunculated tumor. Pain may be associated with a low grade fever, uterine tenderness on palpation, elevated white blood cell count, or peritoneal signs. The discomfort resulting from degenerating fibroids is self-limited, lasting from days to a few weeks, and usually responds to nonsteroidal antiinflammatory drugs. Pelvic magnetic resonance imaging with gadolinium can be useful to make the diagnosis of degeneration since degenerating fibroids do not have enhancement following contrast administration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/57\">",
"     57",
"    </a>",
"    ]. If acute pain is the sole indication for surgery, other disease processes, such as endometriosis and renal colic, or rare diagnoses such as pelvic tuberculosis, should be carefully excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Effects on reproduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leiomyomas that distort the uterine cavity (submucosal or intramural with an intracavitary component) result in difficulty conceiving a pregnancy and an increased risk of miscarriage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/60\">",
"     60",
"    </a>",
"    ]. In addition, leiomyomas have been associated with adverse pregnancy outcomes (eg, placental abruption, fetal growth restriction, and preterm labor and birth). These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=see_link\">",
"     \"Reproductive issues in women with uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15065?source=see_link\">",
"     \"Pregnancy in women with uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequently, a leiomyoma will present with transcervical prolapse, resulting in ulceration or infection.",
"   </p>",
"   <p>",
"    Rare symptoms of fibroid tumors that appear to be related to ectopic hormone production include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polycythemia from autonomous production of erythropoietin [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypercalcemia from autonomous production of PTHrP [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hyperprolactinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/63\">",
"       63",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presumptive diagnosis of uterine myomas is usually based upon the finding of an enlarged, mobile uterus with an irregular contour on bimanual pelvic examination. Typically, an ultrasound is used to confirm the diagnosis and exclude the possibility of another type of uterine mass or an adnexal mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5287492\">",
"    <span class=\"h2\">",
"     Pelvic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough pelvic examination should be performed. On bimanual pelvic examination, an enlarged, mobile uterus with an irregular contour is consistent with a leiomyomatous uterus. The size, contour, and mobility of the uterus should be noted, along with any other findings (eg, adnexal mass, cervical mass). These findings are helpful to follow changes in the uterus over time and to aid surgical planning (eg, plan transverse or vertical incision).",
"   </p>",
"   <p>",
"    Infrequently, on speculum exam, a prolapsed submucosal fibroid may be visible at the external cervical os. These should be removed and are distinguished from a large endocervical or endometrial polyp by the firm consistency of the tissue and by pathologic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=see_link\">",
"     \"Prolapsed uterine leiomyoma (fibroid)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5287506\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a myoma is suspected based upon symptoms or pelvic examination findings, imaging or hysteroscopy are useful to exclude the possibility of another type of uterine mass or an adnexal mass. (See",
"    <a class=\"local\" href=\"#H5289858\">",
"     'Differential diagnosis'",
"    </a>",
"    below.) Computed tomography has little clinical utility in delineating the position of fibroids relative to the endometrium or myometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5287537\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transvaginal ultrasound has high sensitivity (95 to 100 percent) for detecting myomas in uteri less than 10 weeks' size. Localization of fibroids in larger uteri or when there are many tumors is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/65\">",
"     65",
"    </a>",
"    ]. This is the most widely used modality due to its availability and cost-effectiveness.",
"   </p>",
"   <p>",
"    Saline infusion sonography (sonohysterography) improves characterization of the extent of protrusion into the endometrial cavity by submucous myomas and allows identification of some intracavitary lesions not seen on routine ultrasonography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51266 \" href=\"UTD.htm?11/28/11715\">",
"     image 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40823?source=see_link\">",
"     \"Saline infusion sonohysterography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5287677\">",
"    <span class=\"h3\">",
"     Diagnostic hysteroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic hysteroscopy can be performed in the office with a flexible or rigid hysteroscope. When the entire fibroid is visualized arising from a pedicle, or has a broad base, the lesion is hysteroscopically classified as intracavitary. However, when the fibroid abuts the endometrium or protrudes into the myometrium, the depth of penetration cannot be ascertained hysteroscopically. Additionally, hysteroscopy less accurately predicts the size of the myoma compared with ultrasound and sonohysterography [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5287572\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging is the best modality for visualizing the size and location of all uterine myomas and can distinguish among leiomyomas, adenomyosis, and adenomyomas. Due to the expense of this modality, its use is best reserved for surgical planning for complicated procedures. It may also be useful in differentiating leiomyomas from leiomyosarcomas, and before uterine artery embolization since imaging patterns predict uterine artery embolization outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5287645\">",
"    <span class=\"h3\">",
"     Hysterosalpingography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hysterosalpingogram (HSG) is a good technique for defining the contour of the endometrial cavity. It has poor ability to visualize the rest of the myometrium and can falsely identify an intramural fibroid impinging on the uterine cavity as a submucosal fibroid. It is typically used to visualize myomas only when a HSG is needed to evaluate tubal patency in women with infertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24150?source=see_link\">",
"     \"Hysterosalpingography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5289858\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal nonpregnant uterus weighs approximately 70 g. The differential diagnosis of an enlarged uterus includes both benign and malignant conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uterine adenomyosis or adenomyoma",
"     </li>",
"     <li>",
"      Leiomyoma variant",
"     </li>",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Hematometra",
"     </li>",
"     <li>",
"      Uterine sarcoma",
"     </li>",
"     <li>",
"      Uterine carcinosarcoma",
"     </li>",
"     <li>",
"      Endometrial carcinoma",
"     </li>",
"     <li>",
"      Metastatic disease (typically from another reproductive tract primary)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following sections will review aspects of these conditions that are relevant to distinguishing them from leiomyomas and uterine sarcoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16353227\">",
"    <span class=\"h2\">",
"     Benign conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5290489\">",
"    <span class=\"h3\">",
"     Adenomyosis or adenomyoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the etiologies of a uterine mass, adenomyoma is the most likely to resemble a leiomyoma on pelvic imaging and intraoperative examination. Diffuse adenomyosis can also cause uterine enlargement without the presence of a discrete mass.",
"   </p>",
"   <p>",
"    Similar to leiomyomas or uterine sarcoma, adenomyomas typically present with abnormal uterine bleeding. One characteristic that may distinguish adenomyomas from leiomyomas or sarcoma is the presence of dysmenorrhea as a prominent symptom. However, dysmenorrhea is a common gynecologic symptom and may be present in some women with leiomyomas. In addition, adenomyosis and fibroids often occur in the same woman, making differentiation more difficult.",
"   </p>",
"   <p>",
"    Adenomyomas are generally more difficult to excise than leiomyomas. Leiomyomas are typically separated from the adjacent myometrium by a pseudocapsule. With adenomyomas, there is typically no tissue plane between the adenomyoma and the myometrium. Uterine sarcomas are also likely to be difficult to excise.",
"   </p>",
"   <p>",
"    The diagnosis of uterine adenomyosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=see_link&amp;anchor=H7#H7\">",
"     \"Uterine adenomyosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5289872\">",
"    <span class=\"h3\">",
"     Leiomyoma variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of leiomyoma variants that manifest some facets of malignancy, yet lack others. For example, they may metastasize, but not be locally invasive and be histologically benign. These lesions appear to be exceedingly rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17465?source=see_link\">",
"     \"Variants of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16353295\">",
"    <span class=\"h3\">",
"     Other etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is readily distinguishable from other uterine masses with measurement of a serum human chorionic gonadotropin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pelvic sonography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of early pregnancy\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hematometra, a collection of blood within the uterine cavity, occurs most often following after an intrauterine procedure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in women with cervical stenosis and is diagnosed with pelvic imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H28#H28\">",
"     \"Overview of pregnancy termination\", section on 'Hematometra'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adenomatoid tumors are an uncommon type of mass of the female reproductive tract that can be seen in the myometrium or in the adnexa (the most common place is actually next to the fallopian tube) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/69\">",
"     69",
"    </a>",
"    ]. They are mesothelial proliferations and are not histologically related to adenomyosis. They may grossly mimic leiomyomas. &nbsp;",
"   </p>",
"   <p>",
"    In addition, fibroids must be differentiated from other etiologies of abnormal uterine bleeding (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link\">",
"     \"Postmenopausal uterine bleeding\"",
"    </a>",
"    ), pelvic pain (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    ), and infertility (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16353387\">",
"    <span class=\"h2\">",
"     Malignant disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5289879\">",
"    <span class=\"h3\">",
"     Sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine sarcomas are rare. The incidence was 3 to 7 per 100,000 United States (US) population from 1989 to 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/70\">",
"     70",
"    </a>",
"    ], based upon data from the Surveillance, Epidemiology and End Results (SEER) US national cancer database. The median age at diagnosis is approximately 60 years old. The three most common types of uterine sarcomas are clinically indistinguishable: leiomyosarcoma, endometrial stromal sarcoma, and undifferentiated endometrial sarcoma. The prognosis of sarcoma varies somewhat by histologic type, but, in general, the prognosis is poor compared to other gynecologic malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=see_link\">",
"     \"Differentiating uterine leiomyomas (fibroids) from uterine sarcomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5289886\">",
"    <span class=\"h3\">",
"     Carcinosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine carcinosarcomas are rare and highly aggressive tumors with a poor prognosis. The incidence of carcinosarcomas in US women age 35 years or older is approximately 1 to 4 per 100,000 US population. The median age at diagnosis is approximately 62 to 67 years old.",
"   </p>",
"   <p>",
"    Historically, uterine carcinosarcoma was classified as a type of uterine sarcoma, and was termed malignant mixed m&uuml;llerian tumor or mixed mesodermal sarcoma. However, these tumors are now classified as carcinomas since they derive from a monoclonal cancer cell that exhibits sarcomatous metaplasia, rather than a mixture of carcinoma and sarcoma. In addition, the epidemiology, risk factors, and clinical behavior associated with carcinosarcoma also suggest a closer relationship to endometrial carcinoma than to sarcoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44585?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma\", section on 'Epidemiology and risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44585?source=see_link&amp;anchor=H28301161#H28301161\">",
"     \"Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16353208\">",
"    <span class=\"h3\">",
"     Endometrial carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial carcinoma may also result in abnormal uterine bleeding and a uterine mass. However, the diagnosis is typically made with endometrial sampling and imaging usually shows a thickened endometrium; if a mass is present, it is generally confined to the endometrium, except in women with advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;With modern pelvic imaging, we have achieved an increased appreciation of the variability of growth and shrinkage of leiomyomas",
"    <strong>",
"    </strong>",
"    among women of reproductive age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/13,71,72\">",
"     13,71,72",
"    </a>",
"    ]. Prospective studies have found that between 7 to 40 percent of fibroids regress over six months to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/13,71\">",
"     13,71",
"    </a>",
"    ]. In one prospective study of 64 women (mean age 44 years) with fibroids, the average growth rate was 1.2 cm in diameter over 2.5 years (range 0.9 to 6.8 cm) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/71\">",
"     71",
"    </a>",
"    ]. As an example, a study that followed 72 women with a total of 262 fibroids with magnetic resonance imaging reported a median growth rate of 9 percent at six-month follow-up. [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/13\">",
"     13",
"    </a>",
"    ]. There was wide variation in the growth of individual fibroids across all study participants (range -89 percent to +138 percent) and for different fibroids within each woman. Another example was a prospective study in which 36 women with a total of 101 fibroids were evaluated with magnetic resonance imaging at three-month intervals for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/73\">",
"     73",
"    </a>",
"    ]. Increase in volume of &ge;30 percent in a three-month period was found in 37 myomas; rapid growth was more likely in tumors that were &le;5 cm in diameter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5291329\">",
"    <span class=\"h2\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relief of menstrual bleeding symptoms related to fibroids occurs at the time of menopause, when menstrual cyclicity stops and steroid hormone levels wane. Most, but not all, women have shrinkage of leiomyomas at menopause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Women on hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of postmenopausal hormone therapy may cause some women with leiomyomas to continue to have symptoms after menopause. The risk of symptoms may depend, in part, on the location of the fibroid (higher if submucosal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/74\">",
"     74",
"    </a>",
"    ]) and type of estrogen preparation (higher with transdermal estrogen in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/75,76\">",
"     75,76",
"    </a>",
"    ], but not others [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/77\">",
"     77",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    A systematic review including five randomized controlled trials found that postmenopausal hormone therapy was associated with some myoma growth, but this typically occurred without clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/78\">",
"     78",
"    </a>",
"    ]. These findings were confirmed in a subsequent prospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?6/17/6426/abstract/79\">",
"     79",
"    </a>",
"    ]. Thus, the presence of leiomyomas is not a contraindication to use of postmenopausal hormone therapy and postmenopausal hormone therapy does not lead to development of new symptomatic fibroids in most women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H41#H41\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Uterine leiomyomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=see_link\">",
"       \"Patient information: Uterine fibroids (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"       \"Patient information: Uterine fibroids (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5291363\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uterine leiomyomas (fibroids or myomas) are the most common pelvic tumor in women (cumulative incidence by age 50 of &gt;80 percent for black women and almost 70 percent for white women). The incidence of leiomyomas parallels the life cycle changes of the reproductive hormones estrogen and progesterone. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30312569\">",
"       'Race'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leiomyomas are benign monoclonal tumors arising from the smooth muscle cells of the myometrium. Fibroids are often described according to their location in the uterus (submucosal, intramural, subserosal, cervical). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms attributable to uterine myomas can generally be classified into three distinct categories: abnormal uterine bleeding, pelvic pressure and pain, reproductive dysfunction. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presumptive diagnosis of uterine myomas is usually based upon the finding of an enlarged, mobile uterus with an irregular contour on bimanual pelvic examination. Typically, an imaging study is used to confirm the diagnosis and exclude the possibility of another type of uterine mass or an adnexal mass. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transvaginal ultrasound is the most widely used imaging modality for evaluating fibroids due to its availability and cost-effectiveness. Saline infusion sonography (sonohysterography) improves characterization of the extent of protrusion into the endometrial cavity by submucous myomas and allows identification of some intracavitary lesions not seen on routine ultrasonography. (See",
"      <a class=\"local\" href=\"#H5287506\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relief of symptoms related to fibroids usually occurs at the time of menopause, when menstrual cyclicity stops and steroid hormone levels wane. Most, but not all, women have shrinkage of leiomyomas at menopause. Use of postmenopausal hormone therapy may cause some women with leiomyomas to continue to have symptoms after menopause. Hormone therapy may be associated with an increase in size of existing myomas, but not with the development of new myomas. (See",
"      <a class=\"local\" href=\"#H5291329\">",
"       'Postmenopausal women'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Women on hormone therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/1\">",
"      Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/2\">",
"      Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981; 36:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/3\">",
"      Serden SP, Brooks PG. Treatment of abnormal uterine bleeding with the gynecologic resectoscope. J Reprod Med 1991; 36:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/4\">",
"      Wamsteker K, Emanuel MH, de Kruif JH. Transcervical hysteroscopic resection of submucous fibroids for abnormal uterine bleeding: results regarding the degree of intramural extension. Obstet Gynecol 1993; 82:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/5\">",
"      Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990; 94:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/6\">",
"      Downes E, Sikirica V, Gilabert-Estelles J, et al. The burden of uterine fibroids in five European countries. Eur J Obstet Gynecol Reprod Biol 2010; 152:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/7\">",
"      Templeman C, Marshall SF, Clarke CA, et al. Risk factors for surgically removed fibroids in a large cohort of teachers. Fertil Steril 2009; 92:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/8\">",
"      Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997; 90:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/9\">",
"      Wise LA, Palmer JR, Stewart EA, Rosenberg L. Polycystic ovary syndrome and risk of uterine leiomyomata. Fertil Steril 2007; 87:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/10\">",
"      Wise LA, Palmer JR, Cozier YC, et al. Perceived racial discrimination and risk of uterine leiomyomata. Epidemiology 2007; 18:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/11\">",
"      Huyck KL, Panhuysen CI, Cuenco KT, et al. The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters. Am J Obstet Gynecol 2008; 198:168.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/12\">",
"      Kjerulff KH, Langenberg P, Seidman JD, et al. Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J Reprod Med 1996; 41:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/13\">",
"      Peddada SD, Laughlin SK, Miner K, et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci U S A 2008; 105:19887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/14\">",
"      Wilcox LS, Koonin LM, Pokras R, et al. Hysterectomy in the United States, 1988-1990. Obstet Gynecol 1994; 83:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/15\">",
"      Wise LA, Palmer JR, Harlow BL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004; 159:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/16\">",
"      Hodge JC, T Cuenco K, Huyck KL, et al. Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele. Hum Genet 2009; 125:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/17\">",
"      Dragomir AD, Schroeder JC, Connolly A, et al. Potential risk factors associated with subtypes of uterine leiomyomata. Reprod Sci 2010; 17:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/18\">",
"      Adams Hillard PJ. Menstruation in adolescents: what's normal, what's not. Ann N Y Acad Sci 2008; 1135:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/19\">",
"      Baird DD, Newbold R. Prenatal diethylstilbestrol (DES) exposure is associated with uterine leiomyoma development. Reprod Toxicol 2005; 20:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/20\">",
"      Ross RK, Pike MC, Vessey MP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed) 1986; 293:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/21\">",
"      Parazzini F, La Vecchia C, Negri E, et al. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol 1988; 72:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/22\">",
"      Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998; 70:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/23\">",
"      Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology 2003; 14:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/24\">",
"      Laughlin SK, Herring AH, Savitz DA, et al. Pregnancy-related fibroid reduction. Fertil Steril 2010; 94:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/25\">",
"      Chiaffarino F, Parazzini F, La Vecchia C, et al. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol 1999; 106:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/26\">",
"      Parazzini F, Negri E, La Vecchia C, et al. Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol 1992; 79:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/27\">",
"      Lumbiganon P, Rugpao S, Phandhu-fung S, et al. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case--control study. Br J Obstet Gynaecol 1996; 103:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/28\">",
"      Venkatachalam S, Bagratee JS, Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. J Obstet Gynaecol 2004; 24:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/29\">",
"      Laughlin SK, Hartmann KE, Baird DD. Postpartum factors and natural fibroid regression. Am J Obstet Gynecol 2011; 204:496.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/30\">",
"      Frankel T, Benjamin F. Rapid enlargement of a uterine fibroid after clomiphene therapy. J Obstet Gynaecol Br Commonw 1973; 80:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/31\">",
"      Felmingham JE, Corcoran R. Letter: Rapid enlargement of a uterine fibroid after clomiphene therapy. Br J Obstet Gynaecol 1975; 82:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/32\">",
"      Stewart EA, Friedman AJ. Steroidal treatment of myomas : preoperative and long-term medical therapy. Semin Reprod Endocrinol 1992; 10:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/33\">",
"      Sato F, Nishi M, Kudo R, Miyake H. Body fat distribution and uterine leiomyomas. J Epidemiol 1998; 8:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/34\">",
"      Wise LA, Palmer JR, Spiegelman D, et al. Influence of body size and body fat distribution on risk of uterine leiomyomata in U.S. black women. Epidemiology 2005; 16:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/35\">",
"      Marshall LM, Spiegelman D, Manson JE, et al. Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. Epidemiology 1998; 9:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/36\">",
"      Faerstein E, Szklo M, Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol 2001; 153:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/37\">",
"      Terry KL, De Vivo I, Hankinson SE, et al. Anthropometric characteristics and risk of uterine leiomyoma. Epidemiology 2007; 18:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/38\">",
"      Chiaffarino F, Parazzini F, La Vecchia C, et al. Diet and uterine myomas. Obstet Gynecol 1999; 94:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/39\">",
"      Wise LA, Radin RG, Palmer JR, et al. Intake of fruit, vegetables, and carotenoids in relation to risk of uterine leiomyomata. Am J Clin Nutr 2011; 94:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/40\">",
"      Wise LA, Radin RG, Palmer JR, et al. A prospective study of dairy intake and risk of uterine leiomyomata. Am J Epidemiol 2010; 171:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/41\">",
"      Terry KL, Missmer SA, Hankinson SE, et al. Lycopene and other carotenoid intake in relation to risk of uterine leiomyomata. Am J Obstet Gynecol 2008; 198:37.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/42\">",
"      Radin RG, Palmer JR, Rosenberg L, et al. Dietary glycemic index and load in relation to risk of uterine leiomyomata in the Black Women's Health Study. Am J Clin Nutr 2010; 91:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/43\">",
"      Wise LA, Palmer JR, Harlow BL, et al. Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women's Health Study. Hum Reprod 2004; 19:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/44\">",
"      Parazzini F, Negri E, La Vecchia C, et al. Uterine myomas and smoking. Results from an Italian study. J Reprod Med 1996; 41:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/45\">",
"      Faerstein E, Szklo M, Rosenshein NB. Risk factors for uterine leiomyoma: a practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol 2001; 153:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/46\">",
"      Weuve J, Hauser R, Calafat AM, et al. Association of exposure to phthalates with endometriosis and uterine leiomyomata: findings from NHANES, 1999-2004. Environ Health Perspect 2010; 118:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/47\">",
"      Stewart EA, Faur AV. Future Treatments for Fibroids. Contemp ob/gyn 2000; 45:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/48\">",
"      Fraser IS, Critchley HO, Munro MG, et al. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 2007; 87:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/49\">",
"      Wegienka G, Baird DD, Hertz-Picciotto I, et al. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol 2003; 101:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/50\">",
"      Stewart EA, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update 1996; 2:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/51\">",
"      Bansal T, Mehrotra P, Jayasena D, et al. Obstructive nephropathy and chronic kidney disease secondary to uterine leiomyomas. Arch Gynecol Obstet 2009; 279:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/52\">",
"      Fletcher H, Wharfe G, Williams NP, et al. Venous thromboembolism as a complication of uterine fibroids: a retrospective descriptive study. J Obstet Gynaecol 2009; 29:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/53\">",
"      Shiota M, Kotani Y, Umemoto M, et al. Deep-vein thrombosis is associated with large uterine fibroids. Tohoku J Exp Med 2011; 224:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/54\">",
"      Rosenfeld H, Byard RW. Lower extremity deep venous thrombosis with fatal pulmonary thromboembolism caused by benign pelvic space-occupying lesions--an overview. J Forensic Sci 2012; 57:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/55\">",
"      Lippman SA, Warner M, Samuels S, et al. Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril 2003; 80:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/56\">",
"      Ferrero S, Abbamonte LH, Giordano M, et al. Uterine myomas, dyspareunia, and sexual function. Fertil Steril 2006; 86:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/57\">",
"      Laughlin SK, Stewart EA. Uterine leiomyomas: individualizing the approach to a heterogeneous condition. Obstet Gynecol 2011; 117:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/58\">",
"      Mollica G, Pittini L, Minganti E, et al. Elective uterine myomectomy in pregnant women. Clin Exp Obstet Gynecol 1996; 23:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/59\">",
"      Moore AR, Rogers FM, Dietrick D, Smith S. Extrapulmonary tuberculosis in pregnancy masquerading as a degenerating leiomyoma. Obstet Gynecol 2008; 111:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/60\">",
"      Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril 2009; 91:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/61\">",
"      Yoshida M, Koshiyama M, Fujii H, Konishi M. Erythrocytosis and a fibroid. Lancet 1999; 354:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/62\">",
"      Ravakhah K, Gover A, Mukunda BN. Humoral hypercalcemia associated with a uterine fibroid. Ann Intern Med 1999; 130:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/63\">",
"      Cordiano V. Complete remission of hyperprolactinemia and erythrocytosis after hysterectomy for a uterine fibroid in a woman with a previous diagnosis of prolactin-secreting pituitary microadenoma. Ann Hematol 2005; 84:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/64\">",
"      Bradley LD, Falcone T, Magen AB. Radiographic imaging techniques for the diagnosis of abnormal uterine bleeding. Obstet Gynecol Clin North Am 2000; 27:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/65\">",
"      Dueholm M, Lundorf E, Hansen ES, et al. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol 2002; 186:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/66\">",
"      Cicinelli E, Romano F, Anastasio PS, et al. Transabdominal sonohysterography, transvaginal sonography, and hysteroscopy in the evaluation of submucous myomas. Obstet Gynecol 1995; 85:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/67\">",
"      Omary RA, Vasireddy S, Chrisman HB, et al. The effect of pelvic MR imaging on the diagnosis and treatment of women with presumed symptomatic uterine fibroids. J Vasc Interv Radiol 2002; 13:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/68\">",
"      Vedantham S, Sterling KM, Goodwin SC, et al. I. Uterine fibroid embolization: preprocedure assessment. Tech Vasc Interv Radiol 2002; 5:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/69\">",
"      Sangoi AR, McKenney JK, Schwartz EJ, et al. Adenomatoid tumors of the female and male genital tracts: a clinicopathological and immunohistochemical study of 44 cases. Mod Pathol 2009; 22:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/70\">",
"      Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004; 93:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/71\">",
"      DeWaay DJ, Syrop CH, Nygaard IE, et al. Natural history of uterine polyps and leiomyomata. Obstet Gynecol 2002; 100:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/72\">",
"      Kawamura N, Ito F, Ichimura T, et al. Transient rapid growth of uterine leiomyoma in a postmenopausal woman. Oncol Rep 1999; 6:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/73\">",
"      Baird DD, Garrett TA, Laughlin SK, et al. Short-term change in growth of uterine leiomyoma: tumor growth spurts. Fertil Steril 2011; 95:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/74\">",
"      Akkad AA, Habiba MA, Ismail N, et al. Abnormal uterine bleeding on hormone replacement: the importance of intrauterine structural abnormalities. Obstet Gynecol 1995; 86:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/75\">",
"      Sener AB, Se&ccedil;kin NC, Ozmen S, et al. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril 1996; 65:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/76\">",
"      Polatti F, Viazzo F, Colleoni R, Nappi RE. Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT. Maturitas 2000; 37:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/77\">",
"      Palomba S, Sena T, Noia R, et al. Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas. Obstet Gynecol 2001; 98:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/78\">",
"      Ang WC, Farrell E, Vollenhoven B. Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review. Climacteric 2001; 4:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/17/6426/abstract/79\">",
"      Yang CH, Lee JN, Hsu SC, et al. Effect of hormone replacement therapy on uterine fibroids in postmenopausal women--a 3-year study. Maturitas 2002; 43:35.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5486 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6426=[""].join("\n");
var outline_f6_17_6426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5291363\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY AND LOCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30312561\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30312569\">",
"      Race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30312671\">",
"      Menstrual history and parity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5291214\">",
"      Hormonal contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2751993\">",
"      Ovulation induction agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5286725\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30313102\">",
"      Diet, caffeine, and alcohol use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5286804\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5286904\">",
"      Heredity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5286678\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pelvic pressure and pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5287048\">",
"      - Bulk-related symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5287480\">",
"      - Dysmenorrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5287055\">",
"      - Dyspareunia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5287062\">",
"      - Leiomyoma degeneration or torsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Effects on reproduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5287492\">",
"      Pelvic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5287506\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5287537\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5287677\">",
"      - Diagnostic hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5287572\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5287645\">",
"      - Hysterosalpingography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5289858\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16353227\">",
"      Benign conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5290489\">",
"      - Adenomyosis or adenomyoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5289872\">",
"      - Leiomyoma variant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16353295\">",
"      - Other etiologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16353387\">",
"      Malignant disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5289879\">",
"      - Sarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5289886\">",
"      - Carcinosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16353208\">",
"      - Endometrial carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5291329\">",
"      Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Women on hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5291363\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5486\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5486|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/34/8737\" title=\"diagnostic image 1\">",
"      Pedunculated fibroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/28/11715\" title=\"diagnostic image 2\">",
"      Submucosal fibroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5486|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/16/30978\" title=\"figure 1\">",
"      Fibroid anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/32/27143\" title=\"figure 2\">",
"      Submucosal leiomyoma position",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5486|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/47/42740\" title=\"picture 1A\">",
"      Leiomyoma uterus A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/0/13315\" title=\"picture 1B\">",
"      Leiomyoma uterus B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44585?source=related_link\">",
"      Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=related_link\">",
"      Clinical manifestations and diagnosis of early pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=related_link\">",
"      Differentiating uterine leiomyomas (fibroids) from uterine sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25143?source=related_link\">",
"      Histology and pathogenesis of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24150?source=related_link\">",
"      Hysterosalpingography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32601?source=related_link\">",
"      Hysteroscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=related_link\">",
"      Overview of pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=related_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=related_link\">",
"      Patient information: Uterine fibroids (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15065?source=related_link\">",
"      Pregnancy in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=related_link\">",
"      Prolapsed uterine leiomyoma (fibroid)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=related_link\">",
"      Reproductive issues in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40823?source=related_link\">",
"      Saline infusion sonohysterography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=related_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=related_link\">",
"      Uterine adenomyosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17465?source=related_link\">",
"      Variants of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_17_6427="Alkaline diuresis in poisons";
var content_f6_17_6427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents for which alkaline diuresis may enhance elimination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        2,4-D chlorphenoxyacetic acid (herbicide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorpropamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salicylates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diflunisal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoride",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Barbiturates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Phenobarbital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Primidone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Barbital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfonamides",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6427=[""].join("\n");
var outline_f6_17_6427=null;
var title_f6_17_6428="Methods of summarizing studies in systematic reviews";
var content_f6_17_6428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Methods of summarizing studies in systematic reviews",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Approach",
"       </td>",
"       <td class=\"subtitle1\">",
"        Main model",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Qualitative systematic review",
"       </td>",
"       <td>",
"        Qualitative description of evidence",
"       </td>",
"       <td>",
"        May be most appropriate if large degree of heterogeneity among studies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Meta-analysis overall estimate",
"       </td>",
"       <td>",
"        Fixed effects model",
"       </td>",
"       <td>",
"        Assumes a single truth across populations and homogeneity among studies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Random effects model",
"       </td>",
"       <td>",
"        Incorporates between-study heterogeneity. Wider confidence interval than fixed effects model when heterogeneity is present.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meta-analysis of multiple interventions simultaneously",
"       </td>",
"       <td>",
"        Network meta-analysis (mixed or multiple treatment comparison)",
"       </td>",
"       <td>",
"        Estimates relative effects of multiple interventions against each other, even if no individual study analyzed a comparison between 2 or more specific interventions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meta-analysis subgroup analyses",
"       </td>",
"       <td>",
"        Fixed or random effects models",
"       </td>",
"       <td>",
"        May explain heterogeneity. Subject to ecological fallacy. May not be possible due to limited reported data. Arbitrary selection of subgroups may result in spurious findings.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meta-regression",
"       </td>",
"       <td>",
"        Regression across studies",
"       </td>",
"       <td>",
"        May explain heterogeneity. Subject to ecological fallacy. May not be possible due to limited reported data.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Individual patient data meta-analysis",
"       </td>",
"       <td>",
"        Multivariate regression across individuals",
"       </td>",
"       <td>",
"        Allows most complete analysis of data and evaluation of heterogeneity. Costly and resource-intensive.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6428=[""].join("\n");
var outline_f6_17_6428=null;
var title_f6_17_6429="Oral antibiotics human bites";
var content_f6_17_6429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empiric oral antibiotic therapy for human bites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Antibiotic",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dosing for adults",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dosing for children",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Agent of choice:",
"       </p>",
"       <p>",
"        Amoxicillin-clavulanate",
"       </p>",
"      </td>",
"      <td>",
"       875/125 mg twice daily",
"      </td>",
"      <td>",
"       20 mg/kg per dose (amoxicillin component) two times daily (maximum 875 mg amoxicillin and 125 mg clavulinic acid per dose)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Alternate empiric regimens include:&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"3\">",
"       One of the following agents with activity against",
"       <em>",
"        Eikenella",
"       </em>",
"       :",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Doxycycline &Delta;",
"      </td>",
"      <td class=\"sublist_other\">",
"       100 mg twice daily",
"      </td>",
"      <td class=\"sublist_other\">",
"       Not recommended in children &lt;8 years of age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Trimethoprim-sulfamethoxazole &Delta;",
"      </td>",
"      <td class=\"sublist_other\">",
"       1 double strength tablet twice daily",
"      </td>",
"      <td class=\"sublist_other\">",
"       4-5 mg/kg (trimethoprim component) per dose twice daily (maximum 160 mg trimethoprim per dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Penicillin VK",
"      </td>",
"      <td class=\"sublist_other\">",
"       500 mg four times daily",
"      </td>",
"      <td class=\"sublist_other\">",
"       12.5 mg/kg per dose four times daily (maximum 500 mg per dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Cefuroxime",
"      </td>",
"      <td class=\"sublist_other\">",
"       500 mg twice daily",
"      </td>",
"      <td class=\"sublist_other\">",
"       10 mg/kg per dose twice daily (maximum 500 mg per dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\" colspan=\"3\">",
"       Fluoroquinolones (one of the following):",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Ciprofloxacin",
"      </td>",
"      <td class=\"sublist_other\">",
"       500 to 750 mg twice daily",
"      </td>",
"      <td class=\"sublist_other\">",
"       Use with caution in children &lt;18 years of age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Moxifloxacin",
"      </td>",
"      <td class=\"sublist_other\">",
"       400 mg once daily",
"      </td>",
"      <td class=\"sublist_other\">",
"       Use with caution in children &lt;18 years of age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"3\">",
"       <strong>",
"        PLUS",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"3\">",
"       One of the following agents with anaerobic activity:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Metronidazole",
"      </td>",
"      <td class=\"sublist_other\">",
"       500 mg three times daily",
"      </td>",
"      <td class=\"sublist_other\">",
"       10 mg/kg per dose three times daily (maximum 500 mg per dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Clindamycin &Delta;",
"      </td>",
"      <td class=\"sublist_other\">",
"       450 mg three times daily",
"      </td>",
"      <td class=\"sublist_other\">",
"       10 mg/kg per dose three times daily (maximum 450 mg per dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       The following agents have poor activity against",
"       <em>",
"        Eikenella",
"       </em>",
"       and should be avoided:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Cephalexin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Dicloxacillin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Erythromycin",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In patients with infected bite wounds, the clinician may increase the does to 45 mg/kg per dose (amoxicillin component) twice daily (maximum 875 mg amoxicillin and 125 mg clavulinic acid per dose).",
"     <br>",
"      &bull; The preferred regimen for pencillin allergic pediatric patients is trimethoprim-sulfamethoxazole OR cefuroxime PLUS clindamycin (depending on liquid drug availability and palatability).",
"      <br>",
"       &Delta; May also be active against MRSA (check susceptibility testing).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6429=[""].join("\n");
var outline_f6_17_6429=null;
var title_f6_17_6430="Contents: Peds psychosocial emergencies";
var content_f6_17_6430=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Peds psychosocial emergencies",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Peds psychosocial emergencies",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/34/7718\">",
"           Child abuse: Anatomy and pathogenesis of retinal hemorrhages after abusive head trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32985\">",
"           Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/19/40249\">",
"           Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/7/20602\">",
"           Child abuse: Eye findings in children with abusive head trauma (AHT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/2/19497\">",
"           Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/5/35927\">",
"           Child abuse: Social and medicolegal issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/62/18408\">",
"           Child neglect and emotional abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/27/23990\">",
"           Differential diagnosis of suspected child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/23/11641\">",
"           Differential diagnosis of the orthopedic manifestations of child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/11/38071\">",
"           Evaluation and management of suicidal behavior in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35258\">",
"           Evaluation of sexual abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/15/11510\">",
"           Management and sequelae of sexual abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/16/36104\">",
"           Munchausen syndrome by proxy (medical child abuse)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/30/13802\">",
"           Orthopedic aspects of child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/42/40617\">",
"           Peer violence and violence prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/19/24890\">",
"           Physical abuse in children: Diagnostic evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/54/26473\">",
"           Physical abuse in children: Epidemiology and clinical manifestations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/17/23834\">",
"           Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-B37DBC70C8-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f6_17_6430=[""].join("\n");
var outline_f6_17_6430=null;
var title_f6_17_6431="Circadian rhythm of plasma ACTH";
var content_f6_17_6431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circadian rhythm of adrenocorticotropin (ACTH) secretion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 395px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top panel: Pulse analysis of plasma ACTH concentrations in samples obtained at 10-minute intervals for 24 hours. The line represents the plasma ACTH concentration at any moment as predicted by a computer-generated deconvolution program. Bottom panel: Computer-calculated ACTH secretion rate at any moment. The circadian rhythm in plasma ACTH concentrations and, therefore, of cortisol secretion and plasma cortisol concentrations is a function of the variation in the amplitude, not the frequency, of ACTH secretory pulses. To convert pg/mL to pmol/L, multiply by 0.22.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Veldhuis JD, Iranmanesh A, Johnson ML, et al. Amplitude, but not frequency, modulation of adrenocorticotropin secretory bursts gives rise to the nyctohemeral rhythm of the corticotropic axis in man.&nbsp;J Clin Endocrinol Metab 1990; 71:452.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_17_6431=[""].join("\n");
var outline_f6_17_6431=null;
